id	sid	tid	token	lemma	pos
cord-312743-9e4yufo5	1	1	key	key	NN
cord-312743-9e4yufo5	1	2	:	:	:
cord-312743-9e4yufo5	2	1	cord-312743	cord-312743	NNP
cord-312743-9e4yufo5	2	2	-	-	HYPH
cord-312743-9e4yufo5	2	3	9e4yufo5	9e4yufo5	CD
cord-312743-9e4yufo5	2	4	authors	author	NNS
cord-312743-9e4yufo5	2	5	:	:	:
cord-312743-9e4yufo5	2	6	Breiman	Breiman	NNP
cord-312743-9e4yufo5	2	7	,	,	,
cord-312743-9e4yufo5	2	8	Adrien	Adrien	NNP
cord-312743-9e4yufo5	2	9	;	;	:
cord-312743-9e4yufo5	2	10	Ruvën	Ruvën	NNP
cord-312743-9e4yufo5	2	11	-	-	HYPH
cord-312743-9e4yufo5	2	12	Clouet	Clouet	NNP
cord-312743-9e4yufo5	2	13	,	,	,
cord-312743-9e4yufo5	2	14	Nathalie	Nathalie	NNP
cord-312743-9e4yufo5	2	15	;	;	:
cord-312743-9e4yufo5	2	16	Le	Le	NNP
cord-312743-9e4yufo5	2	17	Pendu	Pendu	NNP
cord-312743-9e4yufo5	2	18	,	,	,
cord-312743-9e4yufo5	2	19	Jacques	Jacques	NNP
cord-312743-9e4yufo5	2	20	title	title	NN
cord-312743-9e4yufo5	2	21	:	:	:
cord-312743-9e4yufo5	2	22	Harnessing	harness	VBG
cord-312743-9e4yufo5	2	23	the	the	DT
cord-312743-9e4yufo5	2	24	natural	natural	JJ
cord-312743-9e4yufo5	2	25	anti	anti	JJ
cord-312743-9e4yufo5	2	26	-	-	JJ
cord-312743-9e4yufo5	2	27	glycan	glycan	JJ
cord-312743-9e4yufo5	2	28	immune	immune	JJ
cord-312743-9e4yufo5	2	29	response	response	NN
cord-312743-9e4yufo5	2	30	to	to	TO
cord-312743-9e4yufo5	2	31	limit	limit	VB
cord-312743-9e4yufo5	2	32	the	the	DT
cord-312743-9e4yufo5	2	33	transmission	transmission	NN
cord-312743-9e4yufo5	2	34	of	of	IN
cord-312743-9e4yufo5	2	35	enveloped	envelop	VBN
cord-312743-9e4yufo5	2	36	viruses	virus	NNS
cord-312743-9e4yufo5	2	37	such	such	JJ
cord-312743-9e4yufo5	2	38	as	as	IN
cord-312743-9e4yufo5	2	39	SARS	SARS	NNP
cord-312743-9e4yufo5	2	40	-	-	HYPH
cord-312743-9e4yufo5	2	41	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	2	42	date	date	NN
cord-312743-9e4yufo5	2	43	:	:	:
cord-312743-9e4yufo5	2	44	2020	2020	CD
cord-312743-9e4yufo5	2	45	-	-	HYPH
cord-312743-9e4yufo5	2	46	05	05	CD
cord-312743-9e4yufo5	2	47	-	-	SYM
cord-312743-9e4yufo5	2	48	21	21	CD
cord-312743-9e4yufo5	2	49	journal	journal	NN
cord-312743-9e4yufo5	2	50	:	:	:
cord-312743-9e4yufo5	2	51	PLoS	PLoS	NNP
cord-312743-9e4yufo5	2	52	Pathog	Pathog	NNP
cord-312743-9e4yufo5	2	53	DOI	DOI	NNP
cord-312743-9e4yufo5	2	54	:	:	:
cord-312743-9e4yufo5	2	55	10.1371	10.1371	CD
cord-312743-9e4yufo5	2	56	/	/	SYM
cord-312743-9e4yufo5	2	57	journal.ppat.1008556	journal.ppat.1008556	NNP
cord-312743-9e4yufo5	2	58	sha	sha	NNP
cord-312743-9e4yufo5	2	59	:	:	:
cord-312743-9e4yufo5	2	60	509bb8e8a2851004f8f7f95a7757b189520123a4	509bb8e8a2851004f8f7f95a7757b189520123a4	CD
cord-312743-9e4yufo5	2	61	doc_id	doc_id	CD
cord-312743-9e4yufo5	2	62	:	:	:
cord-312743-9e4yufo5	2	63	312743	312743	CD
cord-312743-9e4yufo5	2	64	cord_uid	cord_uid	NNS
cord-312743-9e4yufo5	2	65	:	:	:
cord-312743-9e4yufo5	3	1	9e4yufo5	9e4yufo5	CD
cord-312743-9e4yufo5	4	1	nan	nan	NNP
cord-312743-9e4yufo5	4	2	domain	domain	NN
cord-312743-9e4yufo5	4	3	[	[	-LRB-
cord-312743-9e4yufo5	4	4	10	10	CD
cord-312743-9e4yufo5	4	5	]	]	-RRB-
cord-312743-9e4yufo5	4	6	.	.	.
cord-312743-9e4yufo5	5	1	The	the	DT
cord-312743-9e4yufo5	5	2	recently	recently	RB
cord-312743-9e4yufo5	5	3	emerged	emerge	VBN
cord-312743-9e4yufo5	5	4	SARS	SARS	NNP
cord-312743-9e4yufo5	5	5	-	-	HYPH
cord-312743-9e4yufo5	5	6	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	5	7	responsible	responsible	JJ
cord-312743-9e4yufo5	5	8	for	for	IN
cord-312743-9e4yufo5	5	9	COVID-19	covid-19	NN
cord-312743-9e4yufo5	5	10	shows	show	VBZ
cord-312743-9e4yufo5	5	11	overall	overall	JJ
cord-312743-9e4yufo5	5	12	conservation	conservation	NN
cord-312743-9e4yufo5	5	13	of	of	IN
cord-312743-9e4yufo5	5	14	the	the	DT
cord-312743-9e4yufo5	5	15	S	S	NNP
cord-312743-9e4yufo5	5	16	protein	protein	NN
cord-312743-9e4yufo5	5	17	glycosylation	glycosylation	NN
cord-312743-9e4yufo5	5	18	sites	site	NNS
cord-312743-9e4yufo5	5	19	.	.	.
cord-312743-9e4yufo5	6	1	The	the	DT
cord-312743-9e4yufo5	6	2	primary	primary	JJ
cord-312743-9e4yufo5	6	3	target	target	NN
cord-312743-9e4yufo5	6	4	organ	organ	NN
cord-312743-9e4yufo5	6	5	of	of	IN
cord-312743-9e4yufo5	6	6	human	human	JJ
cord-312743-9e4yufo5	6	7	coronaviruses	coronaviruse	NNS
cord-312743-9e4yufo5	6	8	,	,	,
cord-312743-9e4yufo5	6	9	including	include	VBG
cord-312743-9e4yufo5	6	10	both	both	CC
cord-312743-9e4yufo5	6	11	SARS	SARS	NNP
cord-312743-9e4yufo5	6	12	and	and	CC
cord-312743-9e4yufo5	6	13	SARS	SARS	NNP
cord-312743-9e4yufo5	6	14	-	-	HYPH
cord-312743-9e4yufo5	6	15	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	6	16	,	,	,
cord-312743-9e4yufo5	6	17	is	be	VBZ
cord-312743-9e4yufo5	6	18	the	the	DT
cord-312743-9e4yufo5	6	19	lung	lung	NN
cord-312743-9e4yufo5	6	20	and	and	CC
cord-312743-9e4yufo5	6	21	both	both	DT
cord-312743-9e4yufo5	6	22	viruses	virus	NNS
cord-312743-9e4yufo5	6	23	use	use	VBP
cord-312743-9e4yufo5	6	24	angiotensin	angiotensin	NN
cord-312743-9e4yufo5	6	25	converting	convert	VBG
cord-312743-9e4yufo5	6	26	enzyme	enzyme	NN
cord-312743-9e4yufo5	6	27	2	2	CD
cord-312743-9e4yufo5	6	28	(	(	-LRB-
cord-312743-9e4yufo5	6	29	ACE2	ACE2	NNP
cord-312743-9e4yufo5	6	30	)	)	-RRB-
cord-312743-9e4yufo5	6	31	as	as	IN
cord-312743-9e4yufo5	6	32	receptor	receptor	NN
cord-312743-9e4yufo5	6	33	[	[	-LRB-
cord-312743-9e4yufo5	6	34	11	11	CD
cord-312743-9e4yufo5	6	35	]	]	-RRB-
cord-312743-9e4yufo5	6	36	.	.	.
cord-312743-9e4yufo5	7	1	Being	be	VBG
cord-312743-9e4yufo5	7	2	expressed	express	VBN
cord-312743-9e4yufo5	7	3	on	on	IN
cord-312743-9e4yufo5	7	4	lung	lung	NN
cord-312743-9e4yufo5	7	5	alveolar	alveolar	NN
cord-312743-9e4yufo5	7	6	epithelial	epithelial	JJ
cord-312743-9e4yufo5	7	7	cells	cell	NNS
cord-312743-9e4yufo5	7	8	,	,	,
cord-312743-9e4yufo5	7	9	chiefly	chiefly	RB
cord-312743-9e4yufo5	7	10	type	type	NN
cord-312743-9e4yufo5	7	11	2	2	CD
cord-312743-9e4yufo5	7	12	pneumocytes	pneumocyte	NNS
cord-312743-9e4yufo5	7	13	,	,	,
cord-312743-9e4yufo5	7	14	[	[	-LRB-
cord-312743-9e4yufo5	7	15	12	12	CD
cord-312743-9e4yufo5	7	16	,	,	,
cord-312743-9e4yufo5	7	17	13	13	CD
cord-312743-9e4yufo5	7	18	]	]	-RRB-
cord-312743-9e4yufo5	7	19	,	,	,
cord-312743-9e4yufo5	7	20	it	-PRON-	PRP
cord-312743-9e4yufo5	7	21	is	be	VBZ
cord-312743-9e4yufo5	7	22	to	to	TO
cord-312743-9e4yufo5	7	23	be	be	VB
cord-312743-9e4yufo5	7	24	expected	expect	VBN
cord-312743-9e4yufo5	7	25	that	that	IN
cord-312743-9e4yufo5	7	26	the	the	DT
cord-312743-9e4yufo5	7	27	glycosylation	glycosylation	NN
cord-312743-9e4yufo5	7	28	of	of	IN
cord-312743-9e4yufo5	7	29	SARS	SARS	NNP
cord-312743-9e4yufo5	7	30	-	-	HYPH
cord-312743-9e4yufo5	7	31	CoV	CoV	NNP
cord-312743-9e4yufo5	7	32	and	and	CC
cord-312743-9e4yufo5	7	33	SARS	SARS	NNP
cord-312743-9e4yufo5	7	34	-	-	HYPH
cord-312743-9e4yufo5	7	35	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	7	36	should	should	MD
cord-312743-9e4yufo5	7	37	be	be	VB
cord-312743-9e4yufo5	7	38	similar	similar	JJ
cord-312743-9e4yufo5	7	39	.	.	.
cord-312743-9e4yufo5	8	1	Using	use	VBG
cord-312743-9e4yufo5	8	2	a	a	DT
cord-312743-9e4yufo5	8	3	cellular	cellular	JJ
cord-312743-9e4yufo5	8	4	experimental	experimental	JJ
cord-312743-9e4yufo5	8	5	model	model	NN
cord-312743-9e4yufo5	8	6	,	,	,
cord-312743-9e4yufo5	8	7	our	-PRON-	PRP$
cord-312743-9e4yufo5	8	8	group	group	NN
cord-312743-9e4yufo5	8	9	showed	show	VBD
cord-312743-9e4yufo5	8	10	that	that	IN
cord-312743-9e4yufo5	8	11	the	the	DT
cord-312743-9e4yufo5	8	12	interaction	interaction	NN
cord-312743-9e4yufo5	8	13	between	between	IN
cord-312743-9e4yufo5	8	14	SARS	SARS	NNP
cord-312743-9e4yufo5	8	15	-	-	HYPH
cord-312743-9e4yufo5	8	16	CoV	CoV	NNP
cord-312743-9e4yufo5	8	17	S	S	NNP
cord-312743-9e4yufo5	8	18	protein	protein	NN
cord-312743-9e4yufo5	8	19	and	and	CC
cord-312743-9e4yufo5	8	20	ACE2	ACE2	NNP
cord-312743-9e4yufo5	8	21	could	could	MD
cord-312743-9e4yufo5	8	22	be	be	VB
cord-312743-9e4yufo5	8	23	specifically	specifically	RB
cord-312743-9e4yufo5	8	24	blocked	block	VBN
cord-312743-9e4yufo5	8	25	in	in	IN
cord-312743-9e4yufo5	8	26	a	a	DT
cord-312743-9e4yufo5	8	27	dose	dose	NN
cord-312743-9e4yufo5	8	28	-	-	HYPH
cord-312743-9e4yufo5	8	29	dependent	dependent	JJ
cord-312743-9e4yufo5	8	30	manner	manner	NN
cord-312743-9e4yufo5	8	31	by	by	IN
cord-312743-9e4yufo5	8	32	anti	anti	JJ
cord-312743-9e4yufo5	8	33	-	-	JJ
cord-312743-9e4yufo5	8	34	A	a	DT
cord-312743-9e4yufo5	8	35	blood	blood	NN
cord-312743-9e4yufo5	8	36	group	group	NN
cord-312743-9e4yufo5	8	37	antibodies	antibody	NNS
cord-312743-9e4yufo5	8	38	when	when	WRB
cord-312743-9e4yufo5	8	39	the	the	DT
cord-312743-9e4yufo5	8	40	S	S	NNP
cord-312743-9e4yufo5	8	41	protein	protein	NN
cord-312743-9e4yufo5	8	42	was	be	VBD
cord-312743-9e4yufo5	8	43	synthesized	synthesize	VBN
cord-312743-9e4yufo5	8	44	by	by	IN
cord-312743-9e4yufo5	8	45	cells	cell	NNS
cord-312743-9e4yufo5	8	46	that	that	WDT
cord-312743-9e4yufo5	8	47	expressed	express	VBD
cord-312743-9e4yufo5	8	48	the	the	DT
cord-312743-9e4yufo5	8	49	A	a	DT
cord-312743-9e4yufo5	8	50	histo	histo	JJ
cord-312743-9e4yufo5	8	51	-	-	HYPH
cord-312743-9e4yufo5	8	52	blood	blood	NN
cord-312743-9e4yufo5	8	53	group	group	NN
cord-312743-9e4yufo5	8	54	antigen	antigen	NN
cord-312743-9e4yufo5	8	55	following	follow	VBG
cord-312743-9e4yufo5	8	56	transfection	transfection	NN
cord-312743-9e4yufo5	8	57	by	by	IN
cord-312743-9e4yufo5	8	58	the	the	DT
cord-312743-9e4yufo5	8	59	appropriate	appropriate	JJ
cord-312743-9e4yufo5	8	60	glycosyltransferases	glycosyltransferase	NNS
cord-312743-9e4yufo5	8	61	cDNA	cdna	NN
cord-312743-9e4yufo5	8	62	[	[	-LRB-
cord-312743-9e4yufo5	8	63	14	14	CD
cord-312743-9e4yufo5	8	64	]	]	-RRB-
cord-312743-9e4yufo5	8	65	.	.	.
cord-312743-9e4yufo5	9	1	These	these	DT
cord-312743-9e4yufo5	9	2	observations	observation	NNS
cord-312743-9e4yufo5	9	3	suggested	suggest	VBD
cord-312743-9e4yufo5	9	4	that	that	IN
cord-312743-9e4yufo5	9	5	,	,	,
cord-312743-9e4yufo5	9	6	when	when	WRB
cord-312743-9e4yufo5	9	7	produced	produce	VBN
cord-312743-9e4yufo5	9	8	in	in	IN
cord-312743-9e4yufo5	9	9	cells	cell	NNS
cord-312743-9e4yufo5	9	10	that	that	WDT
cord-312743-9e4yufo5	9	11	express	express	VBP
cord-312743-9e4yufo5	9	12	the	the	DT
cord-312743-9e4yufo5	9	13	A	A	NNP
cord-312743-9e4yufo5	9	14	or	or	CC
cord-312743-9e4yufo5	9	15	B	b	NN
cord-312743-9e4yufo5	9	16	blood	blood	NN
cord-312743-9e4yufo5	9	17	group	group	NN
cord-312743-9e4yufo5	9	18	enzymes	enzyme	NNS
cord-312743-9e4yufo5	9	19	,	,	,
cord-312743-9e4yufo5	9	20	infectious	infectious	JJ
cord-312743-9e4yufo5	9	21	SARS	SARS	NNP
cord-312743-9e4yufo5	9	22	virions	virion	NNS
cord-312743-9e4yufo5	9	23	are	be	VBP
cord-312743-9e4yufo5	9	24	decorated	decorate	VBN
cord-312743-9e4yufo5	9	25	by	by	IN
cord-312743-9e4yufo5	9	26	the	the	DT
cord-312743-9e4yufo5	9	27	corresponding	corresponding	JJ
cord-312743-9e4yufo5	9	28	glycan	glycan	NN
cord-312743-9e4yufo5	9	29	antigens	antigen	NNS
cord-312743-9e4yufo5	9	30	and	and	CC
cord-312743-9e4yufo5	9	31	that	that	IN
cord-312743-9e4yufo5	9	32	the	the	DT
cord-312743-9e4yufo5	9	33	presence	presence	NN
cord-312743-9e4yufo5	9	34	of	of	IN
cord-312743-9e4yufo5	9	35	anti	anti	JJ
cord-312743-9e4yufo5	9	36	-	-	JJ
cord-312743-9e4yufo5	9	37	A	a	JJ
cord-312743-9e4yufo5	9	38	and	and	CC
cord-312743-9e4yufo5	9	39	anti	anti	JJ
cord-312743-9e4yufo5	9	40	-	-	JJ
cord-312743-9e4yufo5	9	41	B	b	JJ
cord-312743-9e4yufo5	9	42	antibodies	antibody	NNS
cord-312743-9e4yufo5	9	43	in	in	IN
cord-312743-9e4yufo5	9	44	blood	blood	NN
cord-312743-9e4yufo5	9	45	group	group	NN
cord-312743-9e4yufo5	9	46	O	o	NN
cord-312743-9e4yufo5	9	47	individuals	individual	NNS
cord-312743-9e4yufo5	9	48	could	could	MD
cord-312743-9e4yufo5	9	49	prevent	prevent	VB
cord-312743-9e4yufo5	9	50	infection	infection	NN
cord-312743-9e4yufo5	9	51	by	by	IN
cord-312743-9e4yufo5	9	52	blocking	block	VBG
cord-312743-9e4yufo5	9	53	virus	virus	NN
cord-312743-9e4yufo5	9	54	attachment	attachment	NN
cord-312743-9e4yufo5	9	55	and	and	CC
cord-312743-9e4yufo5	9	56	entry	entry	NN
cord-312743-9e4yufo5	9	57	.	.	.
cord-312743-9e4yufo5	10	1	Moreover	moreover	RB
cord-312743-9e4yufo5	10	2	,	,	,
cord-312743-9e4yufo5	10	3	blood	blood	NN
cord-312743-9e4yufo5	10	4	group	group	NN
cord-312743-9e4yufo5	10	5	O	o	NN
cord-312743-9e4yufo5	10	6	individuals	individual	NNS
cord-312743-9e4yufo5	10	7	were	be	VBD
cord-312743-9e4yufo5	10	8	at	at	IN
cord-312743-9e4yufo5	10	9	a	a	DT
cord-312743-9e4yufo5	10	10	much	much	RB
cord-312743-9e4yufo5	10	11	lower	low	JJR
cord-312743-9e4yufo5	10	12	risk	risk	NN
cord-312743-9e4yufo5	10	13	of	of	IN
cord-312743-9e4yufo5	10	14	being	be	VBG
cord-312743-9e4yufo5	10	15	infected	infect	VBN
cord-312743-9e4yufo5	10	16	than	than	IN
cord-312743-9e4yufo5	10	17	non	non	JJ
cord-312743-9e4yufo5	10	18	-	-	JJ
cord-312743-9e4yufo5	10	19	O	o	JJ
cord-312743-9e4yufo5	10	20	individuals	individual	NNS
cord-312743-9e4yufo5	10	21	in	in	IN
cord-312743-9e4yufo5	10	22	a	a	DT
cord-312743-9e4yufo5	10	23	Hong	Hong	NNP
cord-312743-9e4yufo5	10	24	Kong	Kong	NNP
cord-312743-9e4yufo5	10	25	2003	2003	CD
cord-312743-9e4yufo5	10	26	SARS	SARS	NNP
cord-312743-9e4yufo5	10	27	hospital	hospital	NN
cord-312743-9e4yufo5	10	28	outbreak	outbreak	NN
cord-312743-9e4yufo5	10	29	[	[	-LRB-
cord-312743-9e4yufo5	10	30	15	15	CD
cord-312743-9e4yufo5	10	31	]	]	-RRB-
cord-312743-9e4yufo5	10	32	,	,	,
cord-312743-9e4yufo5	10	33	and	and	CC
cord-312743-9e4yufo5	10	34	a	a	DT
cord-312743-9e4yufo5	10	35	similar	similar	JJ
cord-312743-9e4yufo5	10	36	trend	trend	NN
cord-312743-9e4yufo5	10	37	has	have	VBZ
cord-312743-9e4yufo5	10	38	just	just	RB
cord-312743-9e4yufo5	10	39	been	be	VBN
cord-312743-9e4yufo5	10	40	observed	observe	VBN
cord-312743-9e4yufo5	10	41	for	for	IN
cord-312743-9e4yufo5	10	42	COVID-19	COVID-19	NNP
cord-312743-9e4yufo5	10	43	in	in	IN
cord-312743-9e4yufo5	10	44	China	China	NNP
cord-312743-9e4yufo5	10	45	[	[	-LRB-
cord-312743-9e4yufo5	10	46	16	16	CD
cord-312743-9e4yufo5	10	47	]	]	-RRB-
cord-312743-9e4yufo5	10	48	.	.	.
cord-312743-9e4yufo5	11	1	Accordingly	accordingly	RB
cord-312743-9e4yufo5	11	2	,	,	,
cord-312743-9e4yufo5	11	3	blood	blood	NN
cord-312743-9e4yufo5	11	4	group	group	NN
cord-312743-9e4yufo5	11	5	O	o	NN
cord-312743-9e4yufo5	11	6	individuals	individual	NNS
cord-312743-9e4yufo5	11	7	would	would	MD
cord-312743-9e4yufo5	11	8	be	be	VB
cord-312743-9e4yufo5	11	9	at	at	IN
cord-312743-9e4yufo5	11	10	a	a	DT
cord-312743-9e4yufo5	11	11	lesser	less	JJR
cord-312743-9e4yufo5	11	12	risk	risk	NN
cord-312743-9e4yufo5	11	13	of	of	IN
cord-312743-9e4yufo5	11	14	being	be	VBG
cord-312743-9e4yufo5	11	15	infected	infect	VBN
cord-312743-9e4yufo5	11	16	than	than	IN
cord-312743-9e4yufo5	11	17	non	non	JJ
cord-312743-9e4yufo5	11	18	-	-	JJ
cord-312743-9e4yufo5	11	19	O	o	JJ
cord-312743-9e4yufo5	11	20	individuals	individual	NNS
cord-312743-9e4yufo5	11	21	due	due	JJ
cord-312743-9e4yufo5	11	22	to	to	IN
cord-312743-9e4yufo5	11	23	blocking	block	VBG
cord-312743-9e4yufo5	11	24	of	of	IN
cord-312743-9e4yufo5	11	25	potential	potential	JJ
cord-312743-9e4yufo5	11	26	transmission	transmission	NN
cord-312743-9e4yufo5	11	27	events	event	NNS
cord-312743-9e4yufo5	11	28	from	from	IN
cord-312743-9e4yufo5	11	29	either	either	CC
cord-312743-9e4yufo5	11	30	A	A	NNP
cord-312743-9e4yufo5	11	31	,	,	,
cord-312743-9e4yufo5	11	32	B	b	NN
cord-312743-9e4yufo5	11	33	,	,	,
cord-312743-9e4yufo5	11	34	or	or	CC
cord-312743-9e4yufo5	11	35	AB	AB	NNP
cord-312743-9e4yufo5	11	36	individuals	individual	NNS
cord-312743-9e4yufo5	11	37	,	,	,
cord-312743-9e4yufo5	11	38	providing	provide	VBG
cord-312743-9e4yufo5	12	1	anti	anti	JJ
cord-312743-9e4yufo5	12	2	-	-	NNP
cord-312743-9e4yufo5	12	3	A	a	JJ
cord-312743-9e4yufo5	12	4	or	or	CC
cord-312743-9e4yufo5	12	5	anti	anti	JJ
cord-312743-9e4yufo5	12	6	-	-	JJ
cord-312743-9e4yufo5	12	7	B	b	JJ
cord-312743-9e4yufo5	12	8	titers	titer	NNS
cord-312743-9e4yufo5	12	9	are	be	VBP
cord-312743-9e4yufo5	12	10	of	of	IN
cord-312743-9e4yufo5	12	11	sufficient	sufficient	JJ
cord-312743-9e4yufo5	12	12	magnitude	magnitude	NN
cord-312743-9e4yufo5	12	13	(	(	-LRB-
cord-312743-9e4yufo5	12	14	Fig	Fig	NNP
cord-312743-9e4yufo5	12	15	1	1	CD
cord-312743-9e4yufo5	12	16	)	)	-RRB-
cord-312743-9e4yufo5	12	17	.	.	.
cord-312743-9e4yufo5	13	1	Mathematical	mathematical	JJ
cord-312743-9e4yufo5	13	2	modeling	modeling	NN
cord-312743-9e4yufo5	13	3	of	of	IN
cord-312743-9e4yufo5	13	4	the	the	DT
cord-312743-9e4yufo5	13	5	consequences	consequence	NNS
cord-312743-9e4yufo5	13	6	of	of	IN
cord-312743-9e4yufo5	13	7	this	this	DT
cord-312743-9e4yufo5	13	8	potential	potential	JJ
cord-312743-9e4yufo5	13	9	limitation	limitation	NN
cord-312743-9e4yufo5	13	10	of	of	IN
cord-312743-9e4yufo5	13	11	virus	virus	NN
cord-312743-9e4yufo5	13	12	transmission	transmission	NN
cord-312743-9e4yufo5	13	13	suggested	suggest	VBD
cord-312743-9e4yufo5	13	14	that	that	IN
cord-312743-9e4yufo5	13	15	the	the	DT
cord-312743-9e4yufo5	13	16	Hong	Hong	NNP
cord-312743-9e4yufo5	13	17	Kong	Kong	NNP
cord-312743-9e4yufo5	13	18	SARS	SARS	NNP
cord-312743-9e4yufo5	13	19	hospital	hospital	NN
cord-312743-9e4yufo5	13	20	outbreak	outbreak	NN
cord-312743-9e4yufo5	13	21	had	have	VBD
cord-312743-9e4yufo5	13	22	been	be	VBN
cord-312743-9e4yufo5	13	23	slowed	slow	VBN
cord-312743-9e4yufo5	13	24	down	down	RP
cord-312743-9e4yufo5	13	25	to	to	IN
cord-312743-9e4yufo5	13	26	some	some	DT
cord-312743-9e4yufo5	13	27	extent	extent	NN
cord-312743-9e4yufo5	13	28	thanks	thank	NNS
cord-312743-9e4yufo5	13	29	to	to	IN
cord-312743-9e4yufo5	13	30	the	the	DT
cord-312743-9e4yufo5	13	31	ABO	ABO	NNP
cord-312743-9e4yufo5	13	32	genetic	genetic	JJ
cord-312743-9e4yufo5	13	33	polymorphism	polymorphism	NN
cord-312743-9e4yufo5	13	34	and	and	CC
cord-312743-9e4yufo5	13	35	the	the	DT
cord-312743-9e4yufo5	13	36	ensuing	ensue	VBG
cord-312743-9e4yufo5	13	37	neutralizing	neutralize	VBG
cord-312743-9e4yufo5	13	38	anti	anti	JJ
cord-312743-9e4yufo5	13	39	-	-	JJ
cord-312743-9e4yufo5	13	40	A	a	JJ
cord-312743-9e4yufo5	13	41	and	and	CC
cord-312743-9e4yufo5	13	42	anti	anti	JJ
cord-312743-9e4yufo5	13	43	-	-	JJ
cord-312743-9e4yufo5	13	44	B	b	JJ
cord-312743-9e4yufo5	13	45	antibodies	antibody	NNS
cord-312743-9e4yufo5	13	46	.	.	.
cord-312743-9e4yufo5	14	1	It	-PRON-	PRP
cord-312743-9e4yufo5	14	2	further	further	RB
cord-312743-9e4yufo5	14	3	indicated	indicate	VBD
cord-312743-9e4yufo5	14	4	that	that	IN
cord-312743-9e4yufo5	14	5	if	if	IN
cord-312743-9e4yufo5	14	6	anti	anti	JJ
cord-312743-9e4yufo5	14	7	-	-	JJ
cord-312743-9e4yufo5	14	8	blood	blood	JJ
cord-312743-9e4yufo5	14	9	group	group	NN
cord-312743-9e4yufo5	14	10	A	A	NNP
cord-312743-9e4yufo5	14	11	and/	and/	CD
cord-312743-9e4yufo5	14	12	or	or	CC
cord-312743-9e4yufo5	14	13	B	b	NN
cord-312743-9e4yufo5	14	14	titers	titer	NNS
cord-312743-9e4yufo5	14	15	had	have	VBD
cord-312743-9e4yufo5	14	16	always	always	RB
cord-312743-9e4yufo5	14	17	been	be	VBN
cord-312743-9e4yufo5	14	18	high	high	JJ
cord-312743-9e4yufo5	14	19	,	,	,
cord-312743-9e4yufo5	14	20	transmission	transmission	NN
cord-312743-9e4yufo5	14	21	of	of	IN
cord-312743-9e4yufo5	14	22	the	the	DT
cord-312743-9e4yufo5	14	23	virus	virus	NN
cord-312743-9e4yufo5	14	24	,	,	,
cord-312743-9e4yufo5	14	25	in	in	IN
cord-312743-9e4yufo5	14	26	the	the	DT
cord-312743-9e4yufo5	14	27	absence	absence	NN
cord-312743-9e4yufo5	14	28	of	of	IN
cord-312743-9e4yufo5	14	29	any	any	DT
cord-312743-9e4yufo5	14	30	containment	containment	NN
cord-312743-9e4yufo5	14	31	measure	measure	NN
cord-312743-9e4yufo5	14	32	,	,	,
cord-312743-9e4yufo5	14	33	would	would	MD
cord-312743-9e4yufo5	14	34	be	be	VB
cord-312743-9e4yufo5	14	35	largely	largely	RB
cord-312743-9e4yufo5	14	36	impaired	impaired	JJ
cord-312743-9e4yufo5	14	37	and	and	CC
cord-312743-9e4yufo5	14	38	the	the	DT
cord-312743-9e4yufo5	14	39	outbreak	outbreak	NN
cord-312743-9e4yufo5	14	40	slowed	slow	VBD
cord-312743-9e4yufo5	14	41	to	to	IN
cord-312743-9e4yufo5	14	42	a	a	DT
cord-312743-9e4yufo5	14	43	considerable	considerable	JJ
cord-312743-9e4yufo5	14	44	extent	extent	NN
cord-312743-9e4yufo5	14	45	[	[	-LRB-
cord-312743-9e4yufo5	14	46	14	14	CD
cord-312743-9e4yufo5	14	47	]	]	-RRB-
cord-312743-9e4yufo5	14	48	.	.	.
cord-312743-9e4yufo5	15	1	We	-PRON-	PRP
cord-312743-9e4yufo5	15	2	therefore	therefore	RB
cord-312743-9e4yufo5	15	3	hypothesize	hypothesize	VBP
cord-312743-9e4yufo5	15	4	that	that	IN
cord-312743-9e4yufo5	15	5	as	as	IN
cord-312743-9e4yufo5	15	6	they	-PRON-	PRP
cord-312743-9e4yufo5	15	7	are	be	VBP
cord-312743-9e4yufo5	15	8	produced	produce	VBN
cord-312743-9e4yufo5	15	9	in	in	IN
cord-312743-9e4yufo5	15	10	cells	cell	NNS
cord-312743-9e4yufo5	15	11	coexpressing	coexpresse	VBG
cord-312743-9e4yufo5	15	12	the	the	DT
cord-312743-9e4yufo5	15	13	ACE2	ACE2	NNP
cord-312743-9e4yufo5	15	14	receptor	receptor	NN
cord-312743-9e4yufo5	15	15	and	and	CC
cord-312743-9e4yufo5	16	1	either	either	CC
cord-312743-9e4yufo5	16	2	the	the	DT
cord-312743-9e4yufo5	16	3	αGal	αGal	NNPS
cord-312743-9e4yufo5	16	4	,	,	,
cord-312743-9e4yufo5	16	5	NeuGc	neugc	UH
cord-312743-9e4yufo5	16	6	,	,	,
cord-312743-9e4yufo5	16	7	or	or	CC
cord-312743-9e4yufo5	16	8	A	a	NN
cord-312743-9e4yufo5	16	9	/	/	SYM
cord-312743-9e4yufo5	16	10	B	b	NN
cord-312743-9e4yufo5	16	11	blood	blood	NN
cord-312743-9e4yufo5	16	12	group	group	NN
cord-312743-9e4yufo5	16	13	antigens	antigen	NNS
cord-312743-9e4yufo5	16	14	,	,	,
cord-312743-9e4yufo5	16	15	both	both	DT
cord-312743-9e4yufo5	16	16	SARS	SARS	NNP
cord-312743-9e4yufo5	16	17	-	-	HYPH
cord-312743-9e4yufo5	16	18	CoV	CoV	NNP
cord-312743-9e4yufo5	16	19	and	and	CC
cord-312743-9e4yufo5	16	20	SARS	SARS	NNP
cord-312743-9e4yufo5	16	21	-	-	HYPH
cord-312743-9e4yufo5	16	22	CoV2	CoV2	NNP
cord-312743-9e4yufo5	16	23	harbor	harbor	VBP
cord-312743-9e4yufo5	16	24	the	the	DT
cord-312743-9e4yufo5	16	25	corresponding	correspond	VBG
cord-312743-9e4yufo5	16	26	glycan	glycan	NN
cord-312743-9e4yufo5	16	27	epitopes	epitope	NNS
cord-312743-9e4yufo5	16	28	.	.	.
cord-312743-9e4yufo5	17	1	Because	because	IN
cord-312743-9e4yufo5	17	2	of	of	IN
cord-312743-9e4yufo5	17	3	the	the	DT
cord-312743-9e4yufo5	17	4	natural	natural	JJ
cord-312743-9e4yufo5	17	5	immune	immune	JJ
cord-312743-9e4yufo5	17	6	response	response	NN
cord-312743-9e4yufo5	17	7	against	against	IN
cord-312743-9e4yufo5	17	8	these	these	DT
cord-312743-9e4yufo5	17	9	epitopes	epitope	NNS
cord-312743-9e4yufo5	17	10	,	,	,
cord-312743-9e4yufo5	17	11	the	the	DT
cord-312743-9e4yufo5	17	12	αGal	αGal	NNPS
cord-312743-9e4yufo5	17	13	and	and	CC
cord-312743-9e4yufo5	17	14	NeuGc	NeuGc	NNP
cord-312743-9e4yufo5	17	15	xenoantigens	xenoantigens	NNP
cord-312743-9e4yufo5	17	16	would	would	MD
cord-312743-9e4yufo5	17	17	contribute	contribute	VB
cord-312743-9e4yufo5	17	18	to	to	TO
cord-312743-9e4yufo5	17	19	prevent	prevent	VB
cord-312743-9e4yufo5	17	20	cross	cross	JJ
cord-312743-9e4yufo5	17	21	-	-	JJ
cord-312743-9e4yufo5	17	22	species	species	JJ
cord-312743-9e4yufo5	17	23	transmission	transmission	NN
cord-312743-9e4yufo5	17	24	from	from	IN
cord-312743-9e4yufo5	17	25	nonprimate	nonprimate	NN
cord-312743-9e4yufo5	17	26	mammals	mammal	NNS
cord-312743-9e4yufo5	17	27	to	to	IN
cord-312743-9e4yufo5	17	28	humans	human	NNS
cord-312743-9e4yufo5	17	29	,	,	,
cord-312743-9e4yufo5	17	30	while	while	IN
cord-312743-9e4yufo5	17	31	A	a	NN
cord-312743-9e4yufo5	17	32	/	/	SYM
cord-312743-9e4yufo5	17	33	B	b	NN
cord-312743-9e4yufo5	17	34	blood	blood	NN
cord-312743-9e4yufo5	17	35	group	group	NN
cord-312743-9e4yufo5	17	36	antigens	antigen	NNS
cord-312743-9e4yufo5	17	37	would	would	MD
cord-312743-9e4yufo5	17	38	contribute	contribute	VB
cord-312743-9e4yufo5	17	39	to	to	TO
cord-312743-9e4yufo5	17	40	decrease	decrease	VB
cord-312743-9e4yufo5	17	41	and	and	CC
cord-312743-9e4yufo5	17	42	slow	slow	JJ
cord-312743-9e4yufo5	17	43	between	between	IN
cord-312743-9e4yufo5	17	44	-	-	HYPH
cord-312743-9e4yufo5	17	45	human	human	JJ
cord-312743-9e4yufo5	17	46	transmission	transmission	NN
cord-312743-9e4yufo5	17	47	.	.	.
cord-312743-9e4yufo5	18	1	Nonetheless	nonetheless	RB
cord-312743-9e4yufo5	18	2	,	,	,
cord-312743-9e4yufo5	18	3	owing	owe	VBG
cord-312743-9e4yufo5	18	4	to	to	IN
cord-312743-9e4yufo5	18	5	the	the	DT
cord-312743-9e4yufo5	18	6	presence	presence	NN
cord-312743-9e4yufo5	18	7	of	of	IN
cord-312743-9e4yufo5	18	8	individuals	individual	NNS
cord-312743-9e4yufo5	18	9	with	with	IN
cord-312743-9e4yufo5	18	10	low	low	JJ
cord-312743-9e4yufo5	18	11	anti	anti	JJ
cord-312743-9e4yufo5	18	12	-	-	JJ
cord-312743-9e4yufo5	18	13	αGal	αgal	JJ
cord-312743-9e4yufo5	18	14	titers	titer	NNS
cord-312743-9e4yufo5	18	15	,	,	,
cord-312743-9e4yufo5	18	16	occasional	occasional	JJ
cord-312743-9e4yufo5	18	17	cross	cross	JJ
cord-312743-9e4yufo5	18	18	-	-	JJ
cord-312743-9e4yufo5	18	19	species	species	JJ
cord-312743-9e4yufo5	18	20	transmission	transmission	NN
cord-312743-9e4yufo5	18	21	may	may	MD
cord-312743-9e4yufo5	18	22	occur	occur	VB
cord-312743-9e4yufo5	18	23	.	.	.
cord-312743-9e4yufo5	19	1	Interestingly	interestingly	RB
cord-312743-9e4yufo5	19	2	,	,	,
cord-312743-9e4yufo5	19	3	a	a	DT
cord-312743-9e4yufo5	19	4	recent	recent	JJ
cord-312743-9e4yufo5	19	5	genomic	genomic	JJ
cord-312743-9e4yufo5	19	6	analysis	analysis	NN
cord-312743-9e4yufo5	19	7	across	across	IN
cord-312743-9e4yufo5	19	8	vertebrates	vertebrate	NNS
cord-312743-9e4yufo5	19	9	revealed	reveal	VBD
cord-312743-9e4yufo5	19	10	that	that	IN
cord-312743-9e4yufo5	19	11	two	two	CD
cord-312743-9e4yufo5	19	12	bats	bat	NNS
cord-312743-9e4yufo5	19	13	lineages	lineage	NNS
cord-312743-9e4yufo5	19	14	,	,	,
cord-312743-9e4yufo5	19	15	including	include	VBG
cord-312743-9e4yufo5	19	16	Rhinopholus	Rhinopholus	NNP
cord-312743-9e4yufo5	19	17	bats	bat	NNS
cord-312743-9e4yufo5	19	18	suspected	suspect	VBN
cord-312743-9e4yufo5	19	19	to	to	TO
cord-312743-9e4yufo5	19	20	have	have	VB
cord-312743-9e4yufo5	19	21	originated	originate	VBN
cord-312743-9e4yufo5	19	22	the	the	DT
cord-312743-9e4yufo5	19	23	SARS	SARS	NNP
cord-312743-9e4yufo5	19	24	-	-	HYPH
cord-312743-9e4yufo5	19	25	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	19	26	closest	close	JJS
cord-312743-9e4yufo5	19	27	ancestor	ancestor	NN
cord-312743-9e4yufo5	19	28	,	,	,
cord-312743-9e4yufo5	19	29	lost	lose	VBD
cord-312743-9e4yufo5	19	30	their	-PRON-	PRP$
cord-312743-9e4yufo5	19	31	Cmah	Cmah	NNP
cord-312743-9e4yufo5	19	32	gene	gene	NN
cord-312743-9e4yufo5	19	33	function	function	NN
cord-312743-9e4yufo5	19	34	,	,	,
cord-312743-9e4yufo5	19	35	similar	similar	JJ
cord-312743-9e4yufo5	19	36	to	to	IN
cord-312743-9e4yufo5	19	37	humans	human	NNS
cord-312743-9e4yufo5	19	38	[	[	-LRB-
cord-312743-9e4yufo5	19	39	17	17	CD
cord-312743-9e4yufo5	19	40	]	]	-RRB-
cord-312743-9e4yufo5	19	41	.	.	.
cord-312743-9e4yufo5	20	1	The	the	DT
cord-312743-9e4yufo5	20	2	lack	lack	NN
cord-312743-9e4yufo5	20	3	of	of	IN
cord-312743-9e4yufo5	20	4	NeuGc	NeuGc	NNP
cord-312743-9e4yufo5	20	5	xenoantigen	xenoantigen	NNP
cord-312743-9e4yufo5	20	6	on	on	IN
cord-312743-9e4yufo5	20	7	the	the	DT
cord-312743-9e4yufo5	20	8	virions	virion	NNS
cord-312743-9e4yufo5	20	9	produced	produce	VBN
cord-312743-9e4yufo5	20	10	by	by	IN
cord-312743-9e4yufo5	20	11	these	these	DT
cord-312743-9e4yufo5	20	12	bats	bat	NNS
cord-312743-9e4yufo5	20	13	might	may	MD
cord-312743-9e4yufo5	20	14	have	have	VB
cord-312743-9e4yufo5	20	15	facilitated	facilitate	VBN
cord-312743-9e4yufo5	20	16	cross	cross	JJ
cord-312743-9e4yufo5	20	17	-	-	JJ
cord-312743-9e4yufo5	20	18	species	species	JJ
cord-312743-9e4yufo5	20	19	transmission	transmission	NN
cord-312743-9e4yufo5	20	20	.	.	.
cord-312743-9e4yufo5	21	1	Likewise	likewise	RB
cord-312743-9e4yufo5	21	2	,	,	,
cord-312743-9e4yufo5	21	3	impairment	impairment	NN
cord-312743-9e4yufo5	21	4	of	of	IN
cord-312743-9e4yufo5	21	5	transmission	transmission	NN
cord-312743-9e4yufo5	21	6	by	by	IN
cord-312743-9e4yufo5	21	7	the	the	DT
cord-312743-9e4yufo5	21	8	anti	anti	JJ
cord-312743-9e4yufo5	21	9	-	-	JJ
cord-312743-9e4yufo5	21	10	blood	blood	JJ
cord-312743-9e4yufo5	21	11	group	group	NN
cord-312743-9e4yufo5	21	12	antibodies	antibody	NNS
cord-312743-9e4yufo5	21	13	may	may	MD
cord-312743-9e4yufo5	21	14	not	not	RB
cord-312743-9e4yufo5	21	15	work	work	VB
cord-312743-9e4yufo5	21	16	to	to	IN
cord-312743-9e4yufo5	21	17	its	-PRON-	PRP$
cord-312743-9e4yufo5	21	18	full	full	JJ
cord-312743-9e4yufo5	21	19	potential	potential	NN
cord-312743-9e4yufo5	21	20	because	because	IN
cord-312743-9e4yufo5	21	21	of	of	IN
cord-312743-9e4yufo5	21	22	their	-PRON-	PRP$
cord-312743-9e4yufo5	21	23	variable	variable	JJ
cord-312743-9e4yufo5	21	24	titers	titer	NNS
cord-312743-9e4yufo5	21	25	in	in	IN
cord-312743-9e4yufo5	21	26	the	the	DT
cord-312743-9e4yufo5	21	27	population	population	NN
cord-312743-9e4yufo5	21	28	and	and	CC
cord-312743-9e4yufo5	21	29	of	of	IN
cord-312743-9e4yufo5	21	30	the	the	DT
cord-312743-9e4yufo5	21	31	high	high	JJ
cord-312743-9e4yufo5	21	32	affinity	affinity	NN
cord-312743-9e4yufo5	21	33	of	of	IN
cord-312743-9e4yufo5	21	34	the	the	DT
cord-312743-9e4yufo5	21	35	SARS	SARS	NNP
cord-312743-9e4yufo5	21	36	-	-	HYPH
cord-312743-9e4yufo5	21	37	CoV2	CoV2	NNP
cord-312743-9e4yufo5	21	38	for	for	IN
cord-312743-9e4yufo5	21	39	ACE2	ACE2	NNP
cord-312743-9e4yufo5	21	40	[	[	-LRB-
cord-312743-9e4yufo5	21	41	18	18	CD
cord-312743-9e4yufo5	21	42	]	]	-RRB-
cord-312743-9e4yufo5	21	43	,	,	,
cord-312743-9e4yufo5	21	44	rendering	render	VBG
cord-312743-9e4yufo5	21	45	its	-PRON-	PRP$
cord-312743-9e4yufo5	21	46	neutralization	neutralization	NN
cord-312743-9e4yufo5	21	47	more	more	RBR
cord-312743-9e4yufo5	21	48	difficult	difficult	JJ
cord-312743-9e4yufo5	21	49	.	.	.
cord-312743-9e4yufo5	22	1	This	this	DT
cord-312743-9e4yufo5	22	2	leaves	leave	VBZ
cord-312743-9e4yufo5	22	3	room	room	NN
cord-312743-9e4yufo5	22	4	to	to	TO
cord-312743-9e4yufo5	22	5	amplify	amplify	VB
cord-312743-9e4yufo5	22	6	these	these	DT
cord-312743-9e4yufo5	22	7	innate	innate	JJ
cord-312743-9e4yufo5	22	8	mechanisms	mechanism	NNS
cord-312743-9e4yufo5	22	9	of	of	IN
cord-312743-9e4yufo5	22	10	protection	protection	NN
cord-312743-9e4yufo5	22	11	in	in	IN
cord-312743-9e4yufo5	22	12	preparation	preparation	NN
cord-312743-9e4yufo5	22	13	for	for	IN
cord-312743-9e4yufo5	22	14	the	the	DT
cord-312743-9e4yufo5	22	15	next	next	JJ
cord-312743-9e4yufo5	22	16	emergence	emergence	NN
cord-312743-9e4yufo5	22	17	and	and	CC
cord-312743-9e4yufo5	22	18	mitigation	mitigation	NN
cord-312743-9e4yufo5	22	19	of	of	IN
cord-312743-9e4yufo5	22	20	the	the	DT
cord-312743-9e4yufo5	22	21	virus	virus	NN
cord-312743-9e4yufo5	22	22	impact	impact	NN
cord-312743-9e4yufo5	22	23	once	once	IN
cord-312743-9e4yufo5	22	24	emergence	emergence	NN
cord-312743-9e4yufo5	22	25	has	have	VBZ
cord-312743-9e4yufo5	22	26	occurred	occur	VBN
cord-312743-9e4yufo5	22	27	.	.	.
cord-312743-9e4yufo5	23	1	If	if	IN
cord-312743-9e4yufo5	23	2	the	the	DT
cord-312743-9e4yufo5	23	3	antibody	antibody	NN
cord-312743-9e4yufo5	23	4	blocking	block	VBG
cord-312743-9e4yufo5	23	5	effect	effect	NN
cord-312743-9e4yufo5	23	6	can	can	MD
cord-312743-9e4yufo5	23	7	be	be	VB
cord-312743-9e4yufo5	23	8	documented	document	VBN
cord-312743-9e4yufo5	23	9	in	in	IN
cord-312743-9e4yufo5	23	10	vitro	vitro	FW
cord-312743-9e4yufo5	23	11	,	,	,
cord-312743-9e4yufo5	23	12	and	and	CC
cord-312743-9e4yufo5	23	13	possibly	possibly	RB
cord-312743-9e4yufo5	23	14	in	in	IN
cord-312743-9e4yufo5	23	15	vivo	vivo	NNP
cord-312743-9e4yufo5	23	16	,	,	,
cord-312743-9e4yufo5	23	17	it	-PRON-	PRP
cord-312743-9e4yufo5	23	18	will	will	MD
cord-312743-9e4yufo5	23	19	become	become	VB
cord-312743-9e4yufo5	23	20	important	important	JJ
cord-312743-9e4yufo5	23	21	to	to	TO
cord-312743-9e4yufo5	23	22	consider	consider	VB
cord-312743-9e4yufo5	23	23	raising	raise	VBG
cord-312743-9e4yufo5	23	24	the	the	DT
cord-312743-9e4yufo5	23	25	anti	anti	JJ
cord-312743-9e4yufo5	23	26	-	-	JJ
cord-312743-9e4yufo5	23	27	αGal	αGal	NNPS
cord-312743-9e4yufo5	23	28	,	,	,
cord-312743-9e4yufo5	23	29	as	as	RB
cord-312743-9e4yufo5	23	30	well	well	RB
cord-312743-9e4yufo5	23	31	as	as	IN
cord-312743-9e4yufo5	23	32	the	the	DT
cord-312743-9e4yufo5	23	33	anti	anti	JJ
cord-312743-9e4yufo5	23	34	-	-	JJ
cord-312743-9e4yufo5	23	35	A	a	JJ
cord-312743-9e4yufo5	23	36	and	and	CC
cord-312743-9e4yufo5	23	37	anti	anti	JJ
cord-312743-9e4yufo5	23	38	-	-	JJ
cord-312743-9e4yufo5	23	39	B	b	JJ
cord-312743-9e4yufo5	23	40	antibodies	antibody	NNS
cord-312743-9e4yufo5	23	41	titers	titer	NNS
cord-312743-9e4yufo5	23	42	in	in	IN
cord-312743-9e4yufo5	23	43	human	human	JJ
cord-312743-9e4yufo5	23	44	populations	population	NNS
cord-312743-9e4yufo5	23	45	.	.	.
cord-312743-9e4yufo5	24	1	That	that	DT
cord-312743-9e4yufo5	24	2	could	could	MD
cord-312743-9e4yufo5	24	3	be	be	VB
cord-312743-9e4yufo5	24	4	achieved	achieve	VBN
cord-312743-9e4yufo5	24	5	as	as	RB
cord-312743-9e4yufo5	24	6	previously	previously	RB
cord-312743-9e4yufo5	24	7	described	describe	VBN
cord-312743-9e4yufo5	24	8	either	either	CC
cord-312743-9e4yufo5	24	9	by	by	IN
cord-312743-9e4yufo5	24	10	immunizing	immunize	VBG
cord-312743-9e4yufo5	24	11	against	against	IN
cord-312743-9e4yufo5	24	12	inactivated	inactivate	VBN
cord-312743-9e4yufo5	24	13	harmless	harmless	JJ
cord-312743-9e4yufo5	24	14	bacteria	bacteria	NNS
cord-312743-9e4yufo5	24	15	that	that	WDT
cord-312743-9e4yufo5	24	16	harbor	harbor	VBP
cord-312743-9e4yufo5	24	17	the	the	DT
cord-312743-9e4yufo5	24	18	αGal	αGal	NNPS
cord-312743-9e4yufo5	24	19	,	,	,
cord-312743-9e4yufo5	24	20	A	A	NNP
cord-312743-9e4yufo5	24	21	,	,	,
cord-312743-9e4yufo5	24	22	and	and	CC
cord-312743-9e4yufo5	24	23	B	b	NN
cord-312743-9e4yufo5	24	24	epitopes	epitope	NNS
cord-312743-9e4yufo5	24	25	or	or	CC
cord-312743-9e4yufo5	24	26	by	by	IN
cord-312743-9e4yufo5	24	27	immunizing	immunize	VBG
cord-312743-9e4yufo5	24	28	against	against	IN
cord-312743-9e4yufo5	24	29	the	the	DT
cord-312743-9e4yufo5	24	30	corresponding	corresponding	JJ
cord-312743-9e4yufo5	24	31	synthetic	synthetic	JJ
cord-312743-9e4yufo5	24	32	oligosaccharides	oligosaccharide	NNS
cord-312743-9e4yufo5	24	33	linked	link	VBN
cord-312743-9e4yufo5	24	34	to	to	IN
cord-312743-9e4yufo5	24	35	an	an	DT
cord-312743-9e4yufo5	24	36	immunogenic	immunogenic	JJ
cord-312743-9e4yufo5	24	37	scaffold	scaffold	NN
cord-312743-9e4yufo5	24	38	[	[	-LRB-
cord-312743-9e4yufo5	24	39	19	19	CD
cord-312743-9e4yufo5	24	40	,	,	,
cord-312743-9e4yufo5	24	41	20	20	CD
cord-312743-9e4yufo5	24	42	]	]	-RRB-
cord-312743-9e4yufo5	24	43	.	.	.
cord-312743-9e4yufo5	25	1	Raising	raise	VBG
cord-312743-9e4yufo5	25	2	the	the	DT
cord-312743-9e4yufo5	25	3	anti	anti	JJ
cord-312743-9e4yufo5	25	4	-	-	JJ
cord-312743-9e4yufo5	25	5	A	a	JJ
cord-312743-9e4yufo5	25	6	and	and	CC
cord-312743-9e4yufo5	25	7	anti	anti	JJ
cord-312743-9e4yufo5	25	8	-	-	JJ
cord-312743-9e4yufo5	25	9	B	b	JJ
cord-312743-9e4yufo5	25	10	titers	titer	NNS
cord-312743-9e4yufo5	25	11	in	in	IN
cord-312743-9e4yufo5	25	12	the	the	DT
cord-312743-9e4yufo5	25	13	whole	whole	JJ
cord-312743-9e4yufo5	25	14	population	population	NN
cord-312743-9e4yufo5	25	15	carries	carry	VBZ
cord-312743-9e4yufo5	25	16	the	the	DT
cord-312743-9e4yufo5	25	17	risk	risk	NN
cord-312743-9e4yufo5	25	18	of	of	IN
cord-312743-9e4yufo5	25	19	complicating	complicate	VBG
cord-312743-9e4yufo5	25	20	incompatible	incompatible	JJ
cord-312743-9e4yufo5	25	21	platelet	platelet	NN
cord-312743-9e4yufo5	25	22	transfusion	transfusion	NN
cord-312743-9e4yufo5	25	23	as	as	RB
cord-312743-9e4yufo5	25	24	well	well	RB
cord-312743-9e4yufo5	25	25	as	as	IN
cord-312743-9e4yufo5	25	26	increasing	increase	VBG
cord-312743-9e4yufo5	25	27	the	the	DT
cord-312743-9e4yufo5	25	28	risk	risk	NN
cord-312743-9e4yufo5	25	29	of	of	IN
cord-312743-9e4yufo5	25	30	hemolytic	hemolytic	JJ
cord-312743-9e4yufo5	25	31	disease	disease	NN
cord-312743-9e4yufo5	25	32	of	of	IN
cord-312743-9e4yufo5	25	33	the	the	DT
cord-312743-9e4yufo5	25	34	newborn	newborn	NN
cord-312743-9e4yufo5	25	35	in	in	IN
cord-312743-9e4yufo5	25	36	case	case	NN
cord-312743-9e4yufo5	25	37	of	of	IN
cord-312743-9e4yufo5	25	38	mother	mother	NN
cord-312743-9e4yufo5	25	39	-	-	HYPH
cord-312743-9e4yufo5	25	40	infant	infant	NN
cord-312743-9e4yufo5	25	41	ABO	ABO	NNP
cord-312743-9e4yufo5	25	42	incompatibility	incompatibility	NN
cord-312743-9e4yufo5	25	43	.	.	.
cord-312743-9e4yufo5	26	1	These	these	DT
cord-312743-9e4yufo5	26	2	issues	issue	NNS
cord-312743-9e4yufo5	26	3	should	should	MD
cord-312743-9e4yufo5	26	4	be	be	VB
cord-312743-9e4yufo5	26	5	carefully	carefully	RB
cord-312743-9e4yufo5	26	6	dealt	deal	VBN
cord-312743-9e4yufo5	26	7	with	with	IN
cord-312743-9e4yufo5	26	8	.	.	.
cord-312743-9e4yufo5	27	1	Raising	raise	VBG
cord-312743-9e4yufo5	27	2	the	the	DT
cord-312743-9e4yufo5	27	3	anti	anti	JJ
cord-312743-9e4yufo5	27	4	-	-	JJ
cord-312743-9e4yufo5	27	5	NeuGc	neugc	JJ
cord-312743-9e4yufo5	27	6	titers	titer	NNS
cord-312743-9e4yufo5	27	7	might	may	MD
cord-312743-9e4yufo5	27	8	be	be	VB
cord-312743-9e4yufo5	27	9	more	more	RBR
cord-312743-9e4yufo5	27	10	problematic	problematic	JJ
cord-312743-9e4yufo5	27	11	since	since	IN
cord-312743-9e4yufo5	27	12	meat	meat	NN
cord-312743-9e4yufo5	27	13	and	and	CC
cord-312743-9e4yufo5	27	14	dairy	dairy	NN
cord-312743-9e4yufo5	27	15	products	product	NNS
cord-312743-9e4yufo5	27	16	consumption	consumption	NN
cord-312743-9e4yufo5	27	17	allows	allow	VBZ
cord-312743-9e4yufo5	27	18	incorporation	incorporation	NN
cord-312743-9e4yufo5	27	19	of	of	IN
cord-312743-9e4yufo5	27	20	NeuGc	neugc	RB
cord-312743-9e4yufo5	27	21	onto	onto	IN
cord-312743-9e4yufo5	27	22	human	human	JJ
cord-312743-9e4yufo5	27	23	glycans	glycan	NNS
cord-312743-9e4yufo5	27	24	,	,	,
cord-312743-9e4yufo5	27	25	and	and	CC
cord-312743-9e4yufo5	27	26	this	this	DT
cord-312743-9e4yufo5	27	27	may	may	MD
cord-312743-9e4yufo5	27	28	contribute	contribute	VB
cord-312743-9e4yufo5	27	29	to	to	IN
cord-312743-9e4yufo5	27	30	the	the	DT
cord-312743-9e4yufo5	27	31	promotion	promotion	NN
cord-312743-9e4yufo5	27	32	of	of	IN
cord-312743-9e4yufo5	27	33	inflammation	inflammation	NN
cord-312743-9e4yufo5	27	34	and	and	CC
cord-312743-9e4yufo5	27	35	cancer	cancer	NN
cord-312743-9e4yufo5	27	36	progression	progression	NN
cord-312743-9e4yufo5	27	37	as	as	IN
cord-312743-9e4yufo5	27	38	experimentally	experimentally	RB
cord-312743-9e4yufo5	27	39	demonstrated	demonstrate	VBN
cord-312743-9e4yufo5	27	40	[	[	-LRB-
cord-312743-9e4yufo5	27	41	3	3	CD
cord-312743-9e4yufo5	27	42	,	,	,
cord-312743-9e4yufo5	27	43	21	21	CD
cord-312743-9e4yufo5	27	44	]	]	-RRB-
cord-312743-9e4yufo5	27	45	.	.	.
cord-312743-9e4yufo5	28	1	By	by	IN
cord-312743-9e4yufo5	28	2	contrast	contrast	NN
cord-312743-9e4yufo5	28	3	,	,	,
cord-312743-9e4yufo5	28	4	raising	raise	VBG
cord-312743-9e4yufo5	28	5	the	the	DT
cord-312743-9e4yufo5	28	6	anti	anti	JJ
cord-312743-9e4yufo5	28	7	-	-	JJ
cord-312743-9e4yufo5	28	8	αGal	αgal	JJ
cord-312743-9e4yufo5	28	9	titers	titer	NNS
cord-312743-9e4yufo5	28	10	should	should	MD
cord-312743-9e4yufo5	28	11	not	not	RB
cord-312743-9e4yufo5	28	12	carry	carry	VB
cord-312743-9e4yufo5	28	13	any	any	DT
cord-312743-9e4yufo5	28	14	risk	risk	NN
cord-312743-9e4yufo5	28	15	since	since	IN
cord-312743-9e4yufo5	28	16	the	the	DT
cord-312743-9e4yufo5	28	17	antigen	antigen	NN
cord-312743-9e4yufo5	28	18	is	be	VBZ
cord-312743-9e4yufo5	28	19	entirely	entirely	RB
cord-312743-9e4yufo5	28	20	absent	absent	JJ
cord-312743-9e4yufo5	28	21	from	from	IN
cord-312743-9e4yufo5	28	22	human	human	JJ
cord-312743-9e4yufo5	28	23	tissues	tissue	NNS
cord-312743-9e4yufo5	28	24	.	.	.
cord-312743-9e4yufo5	29	1	Blood	blood	NN
cord-312743-9e4yufo5	29	2	groups	group	NNS
cord-312743-9e4yufo5	30	1	A	a	NN
cord-312743-9e4yufo5	30	2	and	and	CC
cord-312743-9e4yufo5	30	3	B	b	NN
cord-312743-9e4yufo5	30	4	might	may	MD
cord-312743-9e4yufo5	30	5	also	also	RB
cord-312743-9e4yufo5	30	6	be	be	VB
cord-312743-9e4yufo5	30	7	harnessed	harness	VBN
cord-312743-9e4yufo5	30	8	to	to	TO
cord-312743-9e4yufo5	30	9	increase	increase	VB
cord-312743-9e4yufo5	30	10	the	the	DT
cord-312743-9e4yufo5	30	11	efficacy	efficacy	NN
cord-312743-9e4yufo5	30	12	of	of	IN
cord-312743-9e4yufo5	30	13	SARS	SARS	NNP
cord-312743-9e4yufo5	30	14	-	-	HYPH
cord-312743-9e4yufo5	30	15	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	30	16	vaccines	vaccine	NNS
cord-312743-9e4yufo5	30	17	.	.	.
cord-312743-9e4yufo5	31	1	Indeed	indeed	RB
cord-312743-9e4yufo5	31	2	,	,	,
cord-312743-9e4yufo5	31	3	the	the	DT
cord-312743-9e4yufo5	31	4	virus	virus	NN
cord-312743-9e4yufo5	31	5	spike	spike	NN
cord-312743-9e4yufo5	31	6	proteins	protein	NNS
cord-312743-9e4yufo5	31	7	,	,	,
cord-312743-9e4yufo5	31	8	which	which	WDT
cord-312743-9e4yufo5	31	9	are	be	VBP
cord-312743-9e4yufo5	31	10	the	the	DT
cord-312743-9e4yufo5	31	11	main	main	JJ
cord-312743-9e4yufo5	31	12	target	target	NN
cord-312743-9e4yufo5	31	13	of	of	IN
cord-312743-9e4yufo5	31	14	currently	currently	RB
cord-312743-9e4yufo5	31	15	designed	design	VBN
cord-312743-9e4yufo5	31	16	vaccines	vaccine	NNS
cord-312743-9e4yufo5	31	17	,	,	,
cord-312743-9e4yufo5	31	18	might	may	MD
cord-312743-9e4yufo5	31	19	be	be	VB
cord-312743-9e4yufo5	31	20	produced	produce	VBN
cord-312743-9e4yufo5	31	21	in	in	IN
cord-312743-9e4yufo5	31	22	cells	cell	NNS
cord-312743-9e4yufo5	31	23	that	that	WDT
cord-312743-9e4yufo5	31	24	are	be	VBP
cord-312743-9e4yufo5	31	25	enzymatically	enzymatically	RB
cord-312743-9e4yufo5	31	26	equipped	equip	VBN
cord-312743-9e4yufo5	31	27	to	to	TO
cord-312743-9e4yufo5	31	28	synthetize	synthetize	VB
cord-312743-9e4yufo5	31	29	A	A	NNP
cord-312743-9e4yufo5	31	30	and	and	CC
cord-312743-9e4yufo5	31	31	B	b	NN
cord-312743-9e4yufo5	31	32	antigens	antigen	NNS
cord-312743-9e4yufo5	31	33	so	so	IN
cord-312743-9e4yufo5	31	34	that	that	IN
cord-312743-9e4yufo5	31	35	the	the	DT
cord-312743-9e4yufo5	31	36	vaccine	vaccine	NN
cord-312743-9e4yufo5	31	37	glycoprotein	glycoprotein	NN
cord-312743-9e4yufo5	31	38	will	will	MD
cord-312743-9e4yufo5	31	39	carry	carry	VB
cord-312743-9e4yufo5	31	40	these	these	DT
cord-312743-9e4yufo5	31	41	epitopes	epitope	NNS
cord-312743-9e4yufo5	31	42	.	.	.
cord-312743-9e4yufo5	32	1	In	in	IN
cord-312743-9e4yufo5	32	2	addition	addition	NN
cord-312743-9e4yufo5	32	3	to	to	IN
cord-312743-9e4yufo5	32	4	generating	generate	VBG
cord-312743-9e4yufo5	32	5	neutralizing	neutralize	VBG
cord-312743-9e4yufo5	32	6	anti	anti	JJ
cord-312743-9e4yufo5	32	7	-	-	JJ
cord-312743-9e4yufo5	32	8	S	s	JJ
cord-312743-9e4yufo5	32	9	protein	protein	NN
cord-312743-9e4yufo5	32	10	,	,	,
cord-312743-9e4yufo5	32	11	the	the	DT
cord-312743-9e4yufo5	32	12	vaccine	vaccine	NN
cord-312743-9e4yufo5	32	13	would	would	MD
cord-312743-9e4yufo5	32	14	stimulate	stimulate	VB
cord-312743-9e4yufo5	32	15	anti	anti	JJ
cord-312743-9e4yufo5	32	16	-	-	JJ
cord-312743-9e4yufo5	32	17	A	a	JJ
cord-312743-9e4yufo5	32	18	and	and	CC
cord-312743-9e4yufo5	32	19	anti	anti	JJ
cord-312743-9e4yufo5	32	20	-	-	JJ
cord-312743-9e4yufo5	32	21	B	b	JJ
cord-312743-9e4yufo5	32	22	responses	response	NNS
cord-312743-9e4yufo5	32	23	that	that	WDT
cord-312743-9e4yufo5	32	24	may	may	MD
cord-312743-9e4yufo5	32	25	contribute	contribute	VB
cord-312743-9e4yufo5	32	26	to	to	IN
cord-312743-9e4yufo5	32	27	the	the	DT
cord-312743-9e4yufo5	32	28	vaccine	vaccine	NN
cord-312743-9e4yufo5	32	29	efficacy	efficacy	NN
cord-312743-9e4yufo5	32	30	in	in	IN
cord-312743-9e4yufo5	32	31	all	all	DT
cord-312743-9e4yufo5	32	32	cases	case	NNS
cord-312743-9e4yufo5	32	33	of	of	IN
cord-312743-9e4yufo5	32	34	ABO	ABO	NNP
cord-312743-9e4yufo5	32	35	incompatible	incompatible	JJ
cord-312743-9e4yufo5	32	36	transmissions	transmission	NNS
cord-312743-9e4yufo5	32	37	.	.	.
cord-312743-9e4yufo5	33	1	In	in	IN
cord-312743-9e4yufo5	33	2	conclusion	conclusion	NN
cord-312743-9e4yufo5	33	3	,	,	,
cord-312743-9e4yufo5	33	4	we	-PRON-	PRP
cord-312743-9e4yufo5	33	5	propose	propose	VBP
cord-312743-9e4yufo5	33	6	to	to	TO
cord-312743-9e4yufo5	33	7	enhance	enhance	VB
cord-312743-9e4yufo5	33	8	the	the	DT
cord-312743-9e4yufo5	33	9	innate	innate	JJ
cord-312743-9e4yufo5	33	10	anti	anti	JJ
cord-312743-9e4yufo5	33	11	-	-	JJ
cord-312743-9e4yufo5	33	12	viral	viral	JJ
cord-312743-9e4yufo5	33	13	protection	protection	NN
cord-312743-9e4yufo5	33	14	conferred	confer	VBN
cord-312743-9e4yufo5	33	15	by	by	IN
cord-312743-9e4yufo5	33	16	natural	natural	JJ
cord-312743-9e4yufo5	33	17	anti	anti	JJ
cord-312743-9e4yufo5	33	18	-	-	JJ
cord-312743-9e4yufo5	33	19	glycan	glycan	JJ
cord-312743-9e4yufo5	33	20	antibodies	antibody	NNS
cord-312743-9e4yufo5	33	21	in	in	IN
cord-312743-9e4yufo5	33	22	order	order	NN
cord-312743-9e4yufo5	33	23	to	to	TO
cord-312743-9e4yufo5	33	24	lower	lower	VB
cord-312743-9e4yufo5	33	25	both	both	CC
cord-312743-9e4yufo5	33	26	the	the	DT
cord-312743-9e4yufo5	33	27	risk	risk	NN
cord-312743-9e4yufo5	33	28	of	of	IN
cord-312743-9e4yufo5	33	29	emergence	emergence	NN
cord-312743-9e4yufo5	33	30	of	of	IN
cord-312743-9e4yufo5	33	31	coronaviruses	coronaviruse	NNS
cord-312743-9e4yufo5	33	32	,	,	,
cord-312743-9e4yufo5	33	33	or	or	CC
cord-312743-9e4yufo5	33	34	other	other	JJ
cord-312743-9e4yufo5	33	35	enveloped	envelop	VBN
cord-312743-9e4yufo5	33	36	viruses	virus	NNS
cord-312743-9e4yufo5	33	37	,	,	,
cord-312743-9e4yufo5	33	38	from	from	IN
cord-312743-9e4yufo5	33	39	a	a	DT
cord-312743-9e4yufo5	33	40	nonprimate	nonprimate	NN
cord-312743-9e4yufo5	33	41	mammalian	mammalian	JJ
cord-312743-9e4yufo5	33	42	species	specie	NNS
cord-312743-9e4yufo5	33	43	and	and	CC
cord-312743-9e4yufo5	33	44	the	the	DT
cord-312743-9e4yufo5	33	45	risk	risk	NN
cord-312743-9e4yufo5	33	46	of	of	IN
cord-312743-9e4yufo5	33	47	transmission	transmission	NN
cord-312743-9e4yufo5	33	48	within	within	IN
cord-312743-9e4yufo5	33	49	the	the	DT
cord-312743-9e4yufo5	33	50	human	human	JJ
cord-312743-9e4yufo5	33	51	population	population	NN
cord-312743-9e4yufo5	33	52	.	.	.
cord-312743-9e4yufo5	34	1	This	this	DT
cord-312743-9e4yufo5	34	2	could	could	MD
cord-312743-9e4yufo5	34	3	add	add	VB
cord-312743-9e4yufo5	34	4	-	-	HYPH
cord-312743-9e4yufo5	34	5	up	up	NN
cord-312743-9e4yufo5	34	6	to	to	IN
cord-312743-9e4yufo5	34	7	other	other	JJ
cord-312743-9e4yufo5	34	8	protection	protection	NN
cord-312743-9e4yufo5	34	9	and	and	CC
cord-312743-9e4yufo5	34	10	containment	containment	NN
cord-312743-9e4yufo5	34	11	measures	measure	NNS
cord-312743-9e4yufo5	34	12	,	,	,
cord-312743-9e4yufo5	34	13	mitigating	mitigate	VBG
cord-312743-9e4yufo5	34	14	the	the	DT
cord-312743-9e4yufo5	34	15	impact	impact	NN
cord-312743-9e4yufo5	34	16	of	of	IN
cord-312743-9e4yufo5	34	17	the	the	DT
cord-312743-9e4yufo5	34	18	epidemic	epidemic	NN
cord-312743-9e4yufo5	34	19	.	.	.
cord-312743-9e4yufo5	35	1	Virions	virion	NNS
cord-312743-9e4yufo5	35	2	produced	produce	VBN
cord-312743-9e4yufo5	35	3	by	by	IN
cord-312743-9e4yufo5	35	4	blood	blood	NN
cord-312743-9e4yufo5	35	5	group	group	NN
cord-312743-9e4yufo5	35	6	O	o	NN
cord-312743-9e4yufo5	35	7	individuals	individual	NNS
cord-312743-9e4yufo5	35	8	are	be	VBP
cord-312743-9e4yufo5	35	9	devoid	devoid	JJ
cord-312743-9e4yufo5	35	10	of	of	IN
cord-312743-9e4yufo5	35	11	A	a	NN
cord-312743-9e4yufo5	35	12	or	or	CC
cord-312743-9e4yufo5	35	13	B	b	NN
cord-312743-9e4yufo5	35	14	antigens	antigen	NNS
cord-312743-9e4yufo5	35	15	and	and	CC
cord-312743-9e4yufo5	35	16	can	can	MD
cord-312743-9e4yufo5	35	17	be	be	VB
cord-312743-9e4yufo5	35	18	fully	fully	RB
cord-312743-9e4yufo5	35	19	transmitted	transmit	VBN
cord-312743-9e4yufo5	35	20	regardless	regardless	RB
cord-312743-9e4yufo5	35	21	of	of	IN
cord-312743-9e4yufo5	35	22	the	the	DT
cord-312743-9e4yufo5	35	23	recipient	recipient	NN
cord-312743-9e4yufo5	35	24	blood	blood	NN
cord-312743-9e4yufo5	35	25	type	type	NN
cord-312743-9e4yufo5	35	26	(	(	-LRB-
cord-312743-9e4yufo5	35	27	full	full	JJ
cord-312743-9e4yufo5	35	28	arrows	arrow	NNS
cord-312743-9e4yufo5	35	29	)	)	-RRB-
cord-312743-9e4yufo5	35	30	.	.	.
cord-312743-9e4yufo5	36	1	Viruses	virus	NNS
cord-312743-9e4yufo5	36	2	produced	produce	VBN
cord-312743-9e4yufo5	36	3	by	by	IN
cord-312743-9e4yufo5	36	4	A	a	NN
cord-312743-9e4yufo5	36	5	and	and	CC
cord-312743-9e4yufo5	36	6	B	b	NN
cord-312743-9e4yufo5	36	7	blood	blood	NN
cord-312743-9e4yufo5	36	8	groups	group	NNS
cord-312743-9e4yufo5	36	9	individuals	individual	NNS
cord-312743-9e4yufo5	36	10	are	be	VBP
cord-312743-9e4yufo5	36	11	decorated	decorate	VBN
cord-312743-9e4yufo5	36	12	by	by	IN
cord-312743-9e4yufo5	36	13	A	a	NN
cord-312743-9e4yufo5	36	14	or	or	CC
cord-312743-9e4yufo5	36	15	B	B	NNP
cord-312743-9e4yufo5	36	16	blood	blood	NN
cord-312743-9e4yufo5	36	17	group	group	NN
cord-312743-9e4yufo5	36	18	epitopes	epitope	NNS
cord-312743-9e4yufo5	36	19	(	(	-LRB-
cord-312743-9e4yufo5	36	20	red	red	JJ
cord-312743-9e4yufo5	36	21	and	and	CC
cord-312743-9e4yufo5	36	22	green	green	JJ
cord-312743-9e4yufo5	36	23	spikes	spike	NNS
cord-312743-9e4yufo5	36	24	,	,	,
cord-312743-9e4yufo5	36	25	respectively	respectively	RB
cord-312743-9e4yufo5	36	26	)	)	-RRB-
cord-312743-9e4yufo5	36	27	and	and	CC
cord-312743-9e4yufo5	36	28	viruses	virus	NNS
cord-312743-9e4yufo5	36	29	produced	produce	VBN
cord-312743-9e4yufo5	36	30	by	by	IN
cord-312743-9e4yufo5	36	31	blood	blood	NN
cord-312743-9e4yufo5	36	32	group	group	NN
cord-312743-9e4yufo5	36	33	AB	AB	NNP
cord-312743-9e4yufo5	36	34	individuals	individual	NNS
cord-312743-9e4yufo5	36	35	are	be	VBP
cord-312743-9e4yufo5	36	36	decorated	decorate	VBN
cord-312743-9e4yufo5	36	37	by	by	IN
cord-312743-9e4yufo5	36	38	both	both	CC
cord-312743-9e4yufo5	36	39	A	A	NNP
cord-312743-9e4yufo5	36	40	and	and	CC
cord-312743-9e4yufo5	36	41	B	b	NN
cord-312743-9e4yufo5	36	42	epitopes	epitope	NNS
cord-312743-9e4yufo5	36	43	.	.	.
cord-312743-9e4yufo5	37	1	Transmission	transmission	NN
cord-312743-9e4yufo5	37	2	of	of	IN
cord-312743-9e4yufo5	37	3	such	such	JJ
cord-312743-9e4yufo5	37	4	viruses	virus	NNS
cord-312743-9e4yufo5	37	5	will	will	MD
cord-312743-9e4yufo5	37	6	be	be	VB
cord-312743-9e4yufo5	37	7	decreased	decrease	VBN
cord-312743-9e4yufo5	37	8	by	by	IN
cord-312743-9e4yufo5	37	9	the	the	DT
cord-312743-9e4yufo5	37	10	presence	presence	NN
cord-312743-9e4yufo5	37	11	of	of	IN
cord-312743-9e4yufo5	37	12	either	either	DT
cord-312743-9e4yufo5	37	13	anti	anti	JJ
cord-312743-9e4yufo5	37	14	-	-	JJ
cord-312743-9e4yufo5	37	15	A	a	JJ
cord-312743-9e4yufo5	37	16	and/or	and/or	CC
cord-312743-9e4yufo5	37	17	anti	anti	NN
cord-312743-9e4yufo5	37	18	-	-	NN
cord-312743-9e4yufo5	37	19	B	b	NN
cord-312743-9e4yufo5	37	20	of	of	IN
cord-312743-9e4yufo5	37	21	the	the	DT
cord-312743-9e4yufo5	37	22	recipient	recipient	NN
cord-312743-9e4yufo5	37	23	(	(	-LRB-
cord-312743-9e4yufo5	37	24	dashed	dash	VBN
cord-312743-9e4yufo5	37	25	arrows	arrow	NNS
cord-312743-9e4yufo5	37	26	)	)	-RRB-
cord-312743-9e4yufo5	37	27	.	.	.
cord-312743-9e4yufo5	38	1	Transmission	transmission	NN
cord-312743-9e4yufo5	38	2	between	between	IN
cord-312743-9e4yufo5	38	3	individuals	individual	NNS
cord-312743-9e4yufo5	38	4	of	of	IN
cord-312743-9e4yufo5	38	5	the	the	DT
cord-312743-9e4yufo5	38	6	same	same	JJ
cord-312743-9e4yufo5	38	7	subtype	subtype	NN
cord-312743-9e4yufo5	38	8	will	will	MD
cord-312743-9e4yufo5	38	9	always	always	RB
cord-312743-9e4yufo5	38	10	be	be	VB
cord-312743-9e4yufo5	38	11	maximal	maximal	JJ
cord-312743-9e4yufo5	38	12	(	(	-LRB-
cord-312743-9e4yufo5	38	13	circular	circular	JJ
cord-312743-9e4yufo5	38	14	arrows	arrow	NNS
cord-312743-9e4yufo5	38	15	)	)	-RRB-
cord-312743-9e4yufo5	38	16	.	.	.
cord-312743-9e4yufo5	39	1	In	in	IN
cord-312743-9e4yufo5	39	2	the	the	DT
cord-312743-9e4yufo5	39	3	presence	presence	NN
cord-312743-9e4yufo5	39	4	of	of	IN
cord-312743-9e4yufo5	39	5	high	high	JJ
cord-312743-9e4yufo5	39	6	-	-	HYPH
cord-312743-9e4yufo5	39	7	titered	titered	JJ
cord-312743-9e4yufo5	39	8	anti	anti	NNP
cord-312743-9e4yufo5	39	9	-	-	NNP
cord-312743-9e4yufo5	39	10	A	a	JJ
cord-312743-9e4yufo5	39	11	and	and	CC
cord-312743-9e4yufo5	39	12	anti	anti	JJ
cord-312743-9e4yufo5	39	13	-	-	JJ
cord-312743-9e4yufo5	39	14	B	b	JJ
cord-312743-9e4yufo5	39	15	antibodies	antibody	NNS
cord-312743-9e4yufo5	39	16	,	,	,
cord-312743-9e4yufo5	39	17	transmissions	transmission	NNS
cord-312743-9e4yufo5	39	18	represented	represent	VBN
cord-312743-9e4yufo5	39	19	by	by	IN
cord-312743-9e4yufo5	39	20	dashed	dash	VBN
cord-312743-9e4yufo5	39	21	arrows	arrow	NNS
cord-312743-9e4yufo5	39	22	should	should	MD
cord-312743-9e4yufo5	39	23	be	be	VB
cord-312743-9e4yufo5	39	24	completely	completely	RB
cord-312743-9e4yufo5	39	25	ablated	ablate	VBN
cord-312743-9e4yufo5	39	26	.	.	.
cord-312743-9e4yufo5	40	1	https://doi.org/10.1371/journal.ppat.1008556.g001	https://doi.org/10.1371/journal.ppat.1008556.g001	XX
cord-312743-9e4yufo5	41	1	Evolution	evolution	NN
cord-312743-9e4yufo5	41	2	of	of	IN
cord-312743-9e4yufo5	41	3	carbohydrate	carbohydrate	NN
cord-312743-9e4yufo5	41	4	antigens	antigen	NNS
cord-312743-9e4yufo5	41	5	-	-	:
cord-312743-9e4yufo5	41	6	microbial	microbial	JJ
cord-312743-9e4yufo5	41	7	forces	force	NNS
cord-312743-9e4yufo5	41	8	shaping	shape	VBG
cord-312743-9e4yufo5	41	9	host	host	NN
cord-312743-9e4yufo5	41	10	glycomes	glycome	NNS
cord-312743-9e4yufo5	41	11	?	?	.
cord-312743-9e4yufo5	42	1	Catastrophic	catastrophic	JJ
cord-312743-9e4yufo5	42	2	-	-	HYPH
cord-312743-9e4yufo5	42	3	selection	selection	NN
cord-312743-9e4yufo5	42	4	"	"	''
cord-312743-9e4yufo5	42	5	interplay	interplay	NN
cord-312743-9e4yufo5	42	6	between	between	IN
cord-312743-9e4yufo5	42	7	enveloped	envelop	VBN
cord-312743-9e4yufo5	42	8	virus	virus	NN
cord-312743-9e4yufo5	42	9	epidemics	epidemic	NNS
cord-312743-9e4yufo5	42	10	,	,	,
cord-312743-9e4yufo5	42	11	mutated	mutate	VBN
cord-312743-9e4yufo5	42	12	genes	gene	NNS
cord-312743-9e4yufo5	42	13	of	of	IN
cord-312743-9e4yufo5	42	14	enzymes	enzyme	NNS
cord-312743-9e4yufo5	42	15	synthesizing	synthesize	VBG
cord-312743-9e4yufo5	42	16	carbohydrate	carbohydrate	NN
cord-312743-9e4yufo5	42	17	antigens	antigen	NNS
cord-312743-9e4yufo5	42	18	,	,	,
cord-312743-9e4yufo5	42	19	and	and	CC
cord-312743-9e4yufo5	42	20	natural	natural	JJ
cord-312743-9e4yufo5	42	21	anticarbohydrate	anticarbohydrate	JJ
cord-312743-9e4yufo5	42	22	antibodies	antibody	NNS
cord-312743-9e4yufo5	42	23	Serum	Serum	NNP
cord-312743-9e4yufo5	42	24	Sickness	sickness	NN
cord-312743-9e4yufo5	42	25	"	"	''
cord-312743-9e4yufo5	42	26	to	to	IN
cord-312743-9e4yufo5	42	27	"	"	``
cord-312743-9e4yufo5	42	28	Xenosialitis	Xenosialitis	NNP
cord-312743-9e4yufo5	42	29	"	"	''
cord-312743-9e4yufo5	42	30	:	:	:
cord-312743-9e4yufo5	42	31	Past	past	NN
cord-312743-9e4yufo5	42	32	,	,	,
cord-312743-9e4yufo5	42	33	Present	Present	NNP
cord-312743-9e4yufo5	42	34	,	,	,
cord-312743-9e4yufo5	42	35	and	and	CC
cord-312743-9e4yufo5	42	36	Future	future	JJ
cord-312743-9e4yufo5	42	37	Significance	significance	NN
cord-312743-9e4yufo5	42	38	of	of	IN
cord-312743-9e4yufo5	42	39	the	the	DT
cord-312743-9e4yufo5	42	40	Non	non	JJ
cord-312743-9e4yufo5	42	41	-	-	JJ
cord-312743-9e4yufo5	42	42	human	human	JJ
cord-312743-9e4yufo5	42	43	Sialic	Sialic	NNP
cord-312743-9e4yufo5	42	44	Acid	Acid	NNP
cord-312743-9e4yufo5	42	45	Neu5Gc	Neu5Gc	NNP
cord-312743-9e4yufo5	42	46	Absence	absence	NN
cord-312743-9e4yufo5	42	47	of	of	IN
cord-312743-9e4yufo5	42	48	Neu5Gc	Neu5Gc	NNP
cord-312743-9e4yufo5	42	49	and	and	CC
cord-312743-9e4yufo5	42	50	Presence	Presence	NNP
cord-312743-9e4yufo5	42	51	of	of	IN
cord-312743-9e4yufo5	42	52	Anti	Anti	NNP
cord-312743-9e4yufo5	42	53	-	-	NNP
cord-312743-9e4yufo5	42	54	Neu5Gc	Neu5Gc	NNP
cord-312743-9e4yufo5	42	55	Antibodies	Antibodies	NNPS
cord-312743-9e4yufo5	42	56	in	in	IN
cord-312743-9e4yufo5	42	57	Humans-	Humans-	NNP
cord-312743-9e4yufo5	43	1	An	an	DT
cord-312743-9e4yufo5	43	2	Evolutionary	Evolutionary	NNP
cord-312743-9e4yufo5	43	3	Perspective	Perspective	NNP
cord-312743-9e4yufo5	43	4	ABO	ABO	NNP
cord-312743-9e4yufo5	43	5	research	research	NN
cord-312743-9e4yufo5	43	6	in	in	IN
cord-312743-9e4yufo5	43	7	the	the	DT
cord-312743-9e4yufo5	43	8	modern	modern	JJ
cord-312743-9e4yufo5	43	9	era	era	NN
cord-312743-9e4yufo5	43	10	of	of	IN
cord-312743-9e4yufo5	43	11	genomics	genomic	NNS
cord-312743-9e4yufo5	43	12	Blood	Blood	NNP
cord-312743-9e4yufo5	43	13	group	group	NN
cord-312743-9e4yufo5	43	14	isoantibody	isoantibody	NN
cord-312743-9e4yufo5	43	15	stimulation	stimulation	NN
cord-312743-9e4yufo5	43	16	in	in	IN
cord-312743-9e4yufo5	43	17	man	man	NN
cord-312743-9e4yufo5	43	18	by	by	IN
cord-312743-9e4yufo5	43	19	feeding	feed	VBG
cord-312743-9e4yufo5	43	20	blood	blood	NN
cord-312743-9e4yufo5	43	21	-	-	HYPH
cord-312743-9e4yufo5	43	22	group	group	NN
cord-312743-9e4yufo5	43	23	active	active	JJ
cord-312743-9e4yufo5	43	24	bacteria	bacteria	NNS
cord-312743-9e4yufo5	43	25	Genetic	genetic	JJ
cord-312743-9e4yufo5	43	26	regulation	regulation	NN
cord-312743-9e4yufo5	43	27	of	of	IN
cord-312743-9e4yufo5	43	28	the	the	DT
cord-312743-9e4yufo5	43	29	expression	expression	NN
cord-312743-9e4yufo5	43	30	of	of	IN
cord-312743-9e4yufo5	43	31	ABH	ABH	NNP
cord-312743-9e4yufo5	43	32	and	and	CC
cord-312743-9e4yufo5	43	33	Lewis	Lewis	NNP
cord-312743-9e4yufo5	43	34	antigens	antigen	NNS
cord-312743-9e4yufo5	43	35	in	in	IN
cord-312743-9e4yufo5	43	36	tissues	tissue	NNS
cord-312743-9e4yufo5	43	37	Quantitation	quantitation	NN
cord-312743-9e4yufo5	43	38	and	and	CC
cord-312743-9e4yufo5	43	39	characterization	characterization	NN
cord-312743-9e4yufo5	43	40	of	of	IN
cord-312743-9e4yufo5	43	41	anti	anti	JJ
cord-312743-9e4yufo5	43	42	-	-	JJ
cord-312743-9e4yufo5	43	43	Galalpha1	Galalpha1	NNP
cord-312743-9e4yufo5	43	44	-	-	HYPH
cord-312743-9e4yufo5	43	45	3Gal	3gal	CD
cord-312743-9e4yufo5	43	46	antibodies	antibody	NNS
cord-312743-9e4yufo5	43	47	in	in	IN
cord-312743-9e4yufo5	43	48	sera	sera	NNP
cord-312743-9e4yufo5	43	49	of	of	IN
cord-312743-9e4yufo5	43	50	200	200	CD
cord-312743-9e4yufo5	43	51	healthy	healthy	JJ
cord-312743-9e4yufo5	43	52	persons	person	NNS
cord-312743-9e4yufo5	44	1	Human	human	JJ
cord-312743-9e4yufo5	44	2	B1	b1	NN
cord-312743-9e4yufo5	44	3	Cells	cell	NNS
cord-312743-9e4yufo5	44	4	are	be	VBP
cord-312743-9e4yufo5	44	5	the	the	DT
cord-312743-9e4yufo5	44	6	Main	Main	NNP
cord-312743-9e4yufo5	44	7	Blood	Blood	NNP
cord-312743-9e4yufo5	44	8	Group	Group	NNP
cord-312743-9e4yufo5	44	9	A	A	NNP
cord-312743-9e4yufo5	44	10	-	-	HYPH
cord-312743-9e4yufo5	44	11	Specific	specific	JJ
cord-312743-9e4yufo5	44	12	B	b	NN
cord-312743-9e4yufo5	44	13	Cells	cell	NNS
cord-312743-9e4yufo5	44	14	That	that	WDT
cord-312743-9e4yufo5	44	15	Have	have	VBP
cord-312743-9e4yufo5	44	16	a	a	DT
cord-312743-9e4yufo5	44	17	Moderate	moderate	JJ
cord-312743-9e4yufo5	44	18	Correlation	correlation	NN
cord-312743-9e4yufo5	44	19	With	with	IN
cord-312743-9e4yufo5	44	20	Anti	Anti	NNP
cord-312743-9e4yufo5	44	21	-	-	NNP
cord-312743-9e4yufo5	44	22	A	A	NNP
cord-312743-9e4yufo5	44	23	Antibody	Antibody	NNP
cord-312743-9e4yufo5	44	24	Titer	Titer	NNP
cord-312743-9e4yufo5	44	25	Unexpected	Unexpected	NNP
cord-312743-9e4yufo5	44	26	Receptor	Receptor	NNP
cord-312743-9e4yufo5	44	27	Functional	functional	JJ
cord-312743-9e4yufo5	44	28	Mimicry	Mimicry	NNP
cord-312743-9e4yufo5	45	1	Elucidates	elucidate	VBZ
cord-312743-9e4yufo5	45	2	Activation	Activation	NNP
cord-312743-9e4yufo5	45	3	of	of	IN
cord-312743-9e4yufo5	45	4	Coronavirus	Coronavirus	NNP
cord-312743-9e4yufo5	45	5	Fusion	Fusion	NNP
cord-312743-9e4yufo5	45	6	Functional	functional	JJ
cord-312743-9e4yufo5	45	7	assessment	assessment	NN
cord-312743-9e4yufo5	45	8	of	of	IN
cord-312743-9e4yufo5	45	9	cell	cell	NN
cord-312743-9e4yufo5	45	10	entry	entry	NN
cord-312743-9e4yufo5	45	11	and	and	CC
cord-312743-9e4yufo5	45	12	receptor	receptor	NN
cord-312743-9e4yufo5	45	13	usage	usage	NN
cord-312743-9e4yufo5	45	14	for	for	IN
cord-312743-9e4yufo5	45	15	SARS	SARS	NNP
cord-312743-9e4yufo5	45	16	-	-	HYPH
cord-312743-9e4yufo5	45	17	CoV-2	CoV-2	NNP
cord-312743-9e4yufo5	45	18	and	and	CC
cord-312743-9e4yufo5	45	19	other	other	JJ
cord-312743-9e4yufo5	45	20	lineage	lineage	NN
cord-312743-9e4yufo5	45	21	B	b	NN
cord-312743-9e4yufo5	45	22	betacoronaviruses	betacoronaviruses	NNP
cord-312743-9e4yufo5	45	23	Tissue	tissue	NN
cord-312743-9e4yufo5	45	24	distribution	distribution	NN
cord-312743-9e4yufo5	45	25	of	of	IN
cord-312743-9e4yufo5	45	26	ACE2	ACE2	NNP
cord-312743-9e4yufo5	45	27	protein	protein	NN
cord-312743-9e4yufo5	45	28	,	,	,
cord-312743-9e4yufo5	45	29	the	the	DT
cord-312743-9e4yufo5	45	30	functional	functional	JJ
cord-312743-9e4yufo5	45	31	receptor	receptor	NN
cord-312743-9e4yufo5	45	32	for	for	IN
cord-312743-9e4yufo5	45	33	SARS	SARS	NNP
cord-312743-9e4yufo5	45	34	coronavirus	coronavirus	NN
cord-312743-9e4yufo5	45	35	.	.	.
cord-312743-9e4yufo5	46	1	A	a	DT
cord-312743-9e4yufo5	46	2	first	first	JJ
cord-312743-9e4yufo5	46	3	step	step	NN
cord-312743-9e4yufo5	46	4	in	in	IN
cord-312743-9e4yufo5	46	5	understanding	understand	VBG
cord-312743-9e4yufo5	46	6	SARS	SARS	NNP
cord-312743-9e4yufo5	46	7	pathogenesis	pathogenesis	NN
cord-312743-9e4yufo5	46	8	Single	single	JJ
cord-312743-9e4yufo5	46	9	-	-	HYPH
cord-312743-9e4yufo5	46	10	cell	cell	NN
cord-312743-9e4yufo5	46	11	RNA	rna	NN
cord-312743-9e4yufo5	46	12	expression	expression	NN
cord-312743-9e4yufo5	46	13	profiling	profiling	NN
cord-312743-9e4yufo5	46	14	of	of	IN
cord-312743-9e4yufo5	46	15	ACE2	ACE2	NNP
cord-312743-9e4yufo5	46	16	,	,	,
cord-312743-9e4yufo5	46	17	the	the	DT
cord-312743-9e4yufo5	46	18	putative	putative	JJ
cord-312743-9e4yufo5	46	19	receptor	receptor	NN
cord-312743-9e4yufo5	46	20	of	of	IN
cord-312743-9e4yufo5	46	21	Wuhan	Wuhan	NNP
cord-312743-9e4yufo5	46	22	2019-nCov	2019-ncov	CD
cord-312743-9e4yufo5	46	23	Inhibition	Inhibition	NNP
cord-312743-9e4yufo5	46	24	of	of	IN
cord-312743-9e4yufo5	46	25	the	the	DT
cord-312743-9e4yufo5	46	26	interaction	interaction	NN
cord-312743-9e4yufo5	46	27	beteen	beteen	IN
cord-312743-9e4yufo5	46	28	the	the	DT
cord-312743-9e4yufo5	46	29	SARS	SARS	NNP
cord-312743-9e4yufo5	46	30	-	-	HYPH
cord-312743-9e4yufo5	46	31	CoV	CoV	NNP
cord-312743-9e4yufo5	46	32	spike	spike	NN
cord-312743-9e4yufo5	46	33	protein	protein	NN
cord-312743-9e4yufo5	46	34	and	and	CC
cord-312743-9e4yufo5	46	35	its	-PRON-	PRP$
cord-312743-9e4yufo5	46	36	cellular	cellular	JJ
cord-312743-9e4yufo5	46	37	receptor	receptor	NN
cord-312743-9e4yufo5	46	38	by	by	IN
cord-312743-9e4yufo5	46	39	anti	anti	JJ
cord-312743-9e4yufo5	46	40	-	-	JJ
cord-312743-9e4yufo5	46	41	histo	histo	JJ
cord-312743-9e4yufo5	46	42	-	-	HYPH
cord-312743-9e4yufo5	46	43	blood	blood	NN
cord-312743-9e4yufo5	46	44	group	group	NN
cord-312743-9e4yufo5	46	45	antibodies	antibody	NNS
cord-312743-9e4yufo5	46	46	ABO	ABO	NNP
cord-312743-9e4yufo5	46	47	blood	blood	NN
cord-312743-9e4yufo5	46	48	group	group	NN
cord-312743-9e4yufo5	46	49	and	and	CC
cord-312743-9e4yufo5	46	50	susceptibility	susceptibility	NN
cord-312743-9e4yufo5	46	51	to	to	IN
cord-312743-9e4yufo5	46	52	severe	severe	JJ
cord-312743-9e4yufo5	46	53	acute	acute	JJ
cord-312743-9e4yufo5	46	54	respiratory	respiratory	JJ
cord-312743-9e4yufo5	46	55	syndrome	syndrome	NN
cord-312743-9e4yufo5	46	56	Relationship	relationship	NN
cord-312743-9e4yufo5	46	57	between	between	IN
cord-312743-9e4yufo5	46	58	the	the	DT
cord-312743-9e4yufo5	46	59	ABO	ABO	NNP
cord-312743-9e4yufo5	46	60	Blood	Blood	NNP
cord-312743-9e4yufo5	46	61	Group	Group	NNP
cord-312743-9e4yufo5	46	62	and	and	CC
cord-312743-9e4yufo5	46	63	the	the	DT
cord-312743-9e4yufo5	46	64	COVID-19	COVID-19	NNP
cord-312743-9e4yufo5	46	65	Susceptib	Susceptib	NNP
cord-312743-9e4yufo5	46	66	Phylogenetic	Phylogenetic	NNP
cord-312743-9e4yufo5	46	67	Distribution	Distribution	NNP
cord-312743-9e4yufo5	46	68	of	of	IN
cord-312743-9e4yufo5	46	69	CMP	CMP	NNP
cord-312743-9e4yufo5	46	70	-	-	HYPH
cord-312743-9e4yufo5	46	71	Neu5Ac	Neu5Ac	NNP
cord-312743-9e4yufo5	46	72	Hydroxylase	Hydroxylase	NNP
cord-312743-9e4yufo5	46	73	(	(	-LRB-
cord-312743-9e4yufo5	46	74	CMAH	CMAH	NNP
cord-312743-9e4yufo5	46	75	)	)	-RRB-
cord-312743-9e4yufo5	46	76	,	,	,
cord-312743-9e4yufo5	46	77	the	the	DT
cord-312743-9e4yufo5	46	78	Enzyme	Enzyme	NNP
cord-312743-9e4yufo5	46	79	Synthetizing	Synthetizing	NNP
cord-312743-9e4yufo5	46	80	the	the	DT
cord-312743-9e4yufo5	46	81	Proinflammatory	Proinflammatory	NNP
cord-312743-9e4yufo5	46	82	Human	Human	NNP
cord-312743-9e4yufo5	46	83	Xenoantigen	Xenoantigen	NNP
cord-312743-9e4yufo5	46	84	Neu5Gc	Neu5Gc	NNP
cord-312743-9e4yufo5	46	85	Cryo	Cryo	NNP
cord-312743-9e4yufo5	46	86	-	-	HYPH
cord-312743-9e4yufo5	46	87	EM	EM	NNP
cord-312743-9e4yufo5	46	88	structure	structure	NN
cord-312743-9e4yufo5	46	89	of	of	IN
cord-312743-9e4yufo5	46	90	the	the	DT
cord-312743-9e4yufo5	46	91	2019-nCoV	2019-ncov	CD
cord-312743-9e4yufo5	46	92	spike	spike	NN
cord-312743-9e4yufo5	46	93	in	in	IN
cord-312743-9e4yufo5	46	94	the	the	DT
cord-312743-9e4yufo5	46	95	prefusion	prefusion	NN
cord-312743-9e4yufo5	46	96	conformation	conformation	NN
cord-312743-9e4yufo5	46	97	Induction	Induction	NNP
cord-312743-9e4yufo5	46	98	of	of	IN
cord-312743-9e4yufo5	46	99	cytolytic	cytolytic	JJ
cord-312743-9e4yufo5	46	100	anti	anti	JJ
cord-312743-9e4yufo5	46	101	-	-	JJ
cord-312743-9e4yufo5	46	102	gal	gal	JJ
cord-312743-9e4yufo5	46	103	antibodies	antibody	NNS
cord-312743-9e4yufo5	46	104	in	in	IN
cord-312743-9e4yufo5	46	105	α-1,3-galactosyltransferase	α-1,3-galactosyltransferase	NN
cord-312743-9e4yufo5	46	106	gene	gene	NN
cord-312743-9e4yufo5	46	107	knockout	knockout	NN
cord-312743-9e4yufo5	46	108	mice	mouse	NNS
cord-312743-9e4yufo5	46	109	by	by	IN
cord-312743-9e4yufo5	46	110	oral	oral	JJ
cord-312743-9e4yufo5	46	111	inoculation	inoculation	NN
cord-312743-9e4yufo5	46	112	with	with	IN
cord-312743-9e4yufo5	46	113	Escherichia	Escherichia	NNP
cord-312743-9e4yufo5	46	114	coli	coli	NNS
cord-312743-9e4yufo5	46	115	O86	O86	NNP
cord-312743-9e4yufo5	46	116	:	:	:
cord-312743-9e4yufo5	46	117	B7	b7	NN
cord-312743-9e4yufo5	46	118	bacteria	bacteria	NNS
cord-312743-9e4yufo5	46	119	Development	Development	NNP
cord-312743-9e4yufo5	46	120	of	of	IN
cord-312743-9e4yufo5	46	121	a	a	DT
cord-312743-9e4yufo5	46	122	-	-	HYPH
cord-312743-9e4yufo5	46	123	Gal	Gal	NNP
cord-312743-9e4yufo5	46	124	-	-	HYPH
cord-312743-9e4yufo5	46	125	Antibody	antibody	NN
cord-312743-9e4yufo5	46	126	Conjugates	Conjugates	NNPS
cord-312743-9e4yufo5	46	127	to	to	TO
cord-312743-9e4yufo5	46	128	Increase	increase	VB
cord-312743-9e4yufo5	46	129	Immune	immune	JJ
cord-312743-9e4yufo5	46	130	Response	response	NN
cord-312743-9e4yufo5	46	131	by	by	IN
cord-312743-9e4yufo5	46	132	Recruiting	recruit	VBG
cord-312743-9e4yufo5	46	133	Natural	Natural	NNP
cord-312743-9e4yufo5	46	134	Antibodies	Antibodies	NNPS
cord-312743-9e4yufo5	47	1	A	a	DT
cord-312743-9e4yufo5	47	2	red	red	JJ
cord-312743-9e4yufo5	47	3	meat	meat	NN
cord-312743-9e4yufo5	47	4	-	-	HYPH
cord-312743-9e4yufo5	47	5	derived	derive	VBN
cord-312743-9e4yufo5	47	6	glycan	glycan	NN
cord-312743-9e4yufo5	47	7	promotes	promote	VBZ
cord-312743-9e4yufo5	47	8	inflammation	inflammation	NN
cord-312743-9e4yufo5	47	9	and	and	CC
cord-312743-9e4yufo5	47	10	cancer	cancer	NN
cord-312743-9e4yufo5	47	11	progression	progression	NN
cord-312743-9e4yufo5	48	1	The	the	DT
cord-312743-9e4yufo5	48	2	authors	author	NNS
cord-312743-9e4yufo5	48	3	are	be	VBP
cord-312743-9e4yufo5	48	4	grateful	grateful	JJ
cord-312743-9e4yufo5	48	5	to	to	IN
cord-312743-9e4yufo5	48	6	Hanane	Hanane	NNP
cord-312743-9e4yufo5	48	7	El	El	NNP
cord-312743-9e4yufo5	48	8	Kenz	Kenz	NNP
cord-312743-9e4yufo5	49	1	(	(	-LRB-
cord-312743-9e4yufo5	49	2	Brugmann	Brugmann	NNP
cord-312743-9e4yufo5	49	3	University	University	NNP
cord-312743-9e4yufo5	49	4	Hospital	Hospital	NNP
cord-312743-9e4yufo5	49	5	,	,	,
cord-312743-9e4yufo5	49	6	Brussels	Brussels	NNP
cord-312743-9e4yufo5	49	7	,	,	,
cord-312743-9e4yufo5	49	8	Belgium	Belgium	NNP
cord-312743-9e4yufo5	49	9	)	)	-RRB-
cord-312743-9e4yufo5	49	10	and	and	CC
cord-312743-9e4yufo5	49	11	France	France	NNP
cord-312743-9e4yufo5	49	12	Pirenne	Pirenne	NNP
cord-312743-9e4yufo5	49	13	(	(	-LRB-
cord-312743-9e4yufo5	49	14	Henri	Henri	NNP
cord-312743-9e4yufo5	49	15	Mondor	Mondor	NNP
cord-312743-9e4yufo5	49	16	University	University	NNP
cord-312743-9e4yufo5	49	17	Hospital	Hospital	NNP
cord-312743-9e4yufo5	49	18	,	,	,
cord-312743-9e4yufo5	49	19	Créteil	Créteil	NNP
cord-312743-9e4yufo5	49	20	,	,	,
cord-312743-9e4yufo5	49	21	France	France	NNP
cord-312743-9e4yufo5	49	22	)	)	-RRB-
cord-312743-9e4yufo5	49	23	for	for	IN
cord-312743-9e4yufo5	49	24	fruitful	fruitful	JJ
cord-312743-9e4yufo5	49	25	discussions	discussion	NNS
cord-312743-9e4yufo5	49	26	and	and	CC
cord-312743-9e4yufo5	49	27	helpful	helpful	JJ
cord-312743-9e4yufo5	49	28	remarks	remark	NNS
cord-312743-9e4yufo5	49	29	.	.	.